An open comparative clinical study on “Thandaga Vatham” (Lumbar Spondylosis) with the evaluation of trial drugs “Naga Chendhuram” (Int) “Moolayoga Nirkundi Thailam” (Ext) and “Varmam Therapy” by Sreedhana, C R
AN OPEN COMPARATIVE CLINICAL STUDY ON “THANDAGA 
VATHAM (LUMBAR SPONDYLOSIS)” WITH THE 
EVALUATION OF TRIAL DRUGS NAGA CHENDHURAM”(INT) 
“MOOLAYOGA  NIRKUNDI  THAILAM” (EXT)  AND  
“VARMAM  THERAPY”. 
The dissertation Submitted by 
Dr. C. R. SREEDHANA B.S.M.S  
Registration No. 321413105 
Under the Guidance of  
Dr. M.MOHAMED MUSTHAFA, M.D(S)  
Dissertation submitted to 
THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY  
CHENNAI-600032  
For the partial fulfillment of the 
Requirement to the Degree of 
DOCTOR OF MEDICINE (SIDDHA)  
BRANCH-III-SIRAPPU MARUTHUVAM  
 
POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
THE GOVERNMENT SIDDHA MEDICAL COLLEGE  
CHENNAI -106  
OCTOBER 2017  
 GOVT. SIDDHA MEDICAL COLLEGE, CHENNAI-106  
 
DECLARATION BY THE CANDIDATE 
 
 
      I hereby declare that this dissertation entitled An open comparative 
clinical study on “Thandaga Vatham (Lumbar Spondylosis)” with the evaluation 
of trial drugs “Naga Chendhuram” (Int) “Moolayoga  Nirkundi  Thailam” (Ext)  
and  “Varmam  Therapy” is a bonafide and genuine research work carried out by 
me under the guidance of  Dr. M. MOHAMED MUSTHAFA, M.D (S), Post 
Graduate Department of Sirappu Maruthuvam, Govt. Siddha Medical College, 
Arumbakkam, Chennai- 600106 and the dissertation has not formed the basis for the 
award of any Degree, Diploma, Fellowship or other similar title.  
 
 
 
Date:         Signature of the Candidate  
Place: Chennai                    Dr.C. R. SREEDHANA 
 
 
 
 
 
 
 
 
 
 GOVT. SIDDHA MEDICAL COLLEGE, CHENNAI-600106 
 
CERTIFICATE BY THE GUIDE 
 
This is to certify that the dissertation entitled An open comparative clinical 
study on “Thandaga Vatham (Lumbar Spondylosis)” with the evaluation of trial 
drugs “Naga Chendhuram” (Int) “Moolayoga  Nirkundi  Thailam” (Ext)  and  
“Varmam  Therapy” is  submitted to the Tamilnadu Dr. M. G. R. Medical 
University in partial fulfillment of the requirements for the award of degree of M.D 
(Siddha) is the bonafide and genuine research work done by C R SREEDHANA 
under my supervision and guidance. The dissertation has not formed the basis for the 
award of any Degree, Diploma, and Associate ship, Fellowship or other similar title. 
 
 
 
Date:               Seal & Signature of the Guide  
Place: Chennai     Dr. M. MOHAMED MUSTHAFA, M. D (S),  
 
 
 
 
 
 
 
 
ENDORSEMENT BY THE HOD, PRINCIPAL/HEAD OF THE 
INSTITUTION 
 
This is to certify that the dissertation entitled An open comparative clinical 
study on “Thandaga Vatham (Lumbar Spondylosis)” with the evaluation of trial 
drug “Naga Chendhuram” (Int) “Moolayoga  Nirkundi  Thailam” (Ext)  and  
“Varmam  Therapy” is a bonafide work carried out by C R SREEDHANA during 
the year 2014-2017 under the guidance of Dr.M.MOHAMED MUSTHAFA, M.D (S), 
Post Graduate Department of Sirappu Maruthuvam, Govt. Siddha Medical College, 
Chennai - 600 106.  
 
 
Seal & Signature of the HOD             Seal & Signature of the Principal  
         
        
 
 
Date:          Date:  
Place: Chennai        Place: Chennai 
    ACKNOWLEDGEMENT 
First of all I am grateful to Almighty God who in every moment of life always 
with me and blessed me.  
No words make articulate to acknowledge didactic guidance rendered by my 
guide Dr.M. MOHAMED MUSTHAFA M.D(s), Reader, Government Siddha Medical 
College, Chennai. I sincerely express my boundless reverence for his excellent guidance, 
constant encouragement, timely advice and thoughtful criticism. 
It is a time for me to express my gratitude to the Vice - chancellor.  The 
Tamilnadu Dr.M.G.R Medical University, Guindy, Chennai and to the Commissioner of 
Indian Medicine and Homeopathy Department, Arumbakkam, Chennai-106 for the 
giving permission to do the dissertation. 
I convey my thanks to Prof. Dr. K. KANAGAVALLI M.D. (S), Principal, Govt 
Siddha Medical College, Arumbakkam for providing all favour facilities in the college. 
It is my gratitude to Dr.G.SEKAR M.D. (S), post graduate Dept of Sirappu 
Maruthuvam, for his support in this study. 
I would like to show my gratitude to Dr.T.R.SIDDIQUE ALI M.D. (S), Post 
Graduate Dept of Sirappu Maruthuvam for his support in this study. 
I would like to convey my gratitude to Prof. Dr.V.VELPANDIAN, M.D. (S), 
PhD. PG Dept of Gunapadam, with his inspiration and great efforts to explain the 
Pharmacological activity for my study. 
It is my privilege to express intense gratitude to the Prof. SELVARAJ, Head of 
the Department, Dept of Bio chemistry, Govt Siddha Medical College, Arumbakkam, 
Chennai-600106. 
It is my gratitude to the Prof. SURESH KUMAR, Ph.D., Head of the 
Department, Dept of Microbiology, Govt Siddha Medical College, Arumbakkam, 
Chennai-600106.giving me valuable knowledge about my in-vitro study. 
It is my gratitude to the Mr.S. SANKARANARAYANAN, Ph.D, Head of the 
Department, Dept of Medicinal Botany, Govt Siddha Medical College, Arumbakkam, 
Chennai-600106 giving me valuable knowledge about my in-vitro study. 
My sincere thanks to Dr. P. SATHYA RAJESWARAN, M.D.(S), Scientist II, 
Central Research Institute, Chennai, His skills and advices were of great value for 
completing my work. 
My sincere thanks to Chairman and Members of Institutional Ethical 
Committee (IEC) Members, Government Siddha Medical College, Chennai for their 
approval. 
I am very much grateful to Mrs.SHAKILA M.Sc, PhD, Research officer SCRI, 
Chennai-106, for their guidance and support in physico- chemical analysis and 
authentication of metals and minerals. 
           I express my sincere thanks to Dr. P. MURALI DHARAN, Pharmacologist,C. L. 
Baid Mehta College of pharmacology, Thoraipakkam for his assistance in the toxicity 
studies. 
My sincere thanks to Prof.RAJESH  Biogenix Research Institute, Trivandrum, 
for his assistance in my pharmacological studies. 
 I wish to thank DR. B. JANARTHANAM, Poonga Biotech Research Centre, 
Chennai for helping me to finish my heavy metal analysis. 
It is a pleasure to thank for all the LABORATORY STAFFS of Govt Siddha Medical 
College and Arignar Anna Govt hospital for Indian Medicine & Homeopathy, 
Arumbakkam, Chennai-106. 
 I wish to thank Dr. MANIVASAGAM B.S.M.S, M.sc Epidemiology for helping 
to do Biostatistical analysis. 
I am very thankful to my PATIENTS for their kind co-operation who had 
participated in this trial.  
      My special thanks to my senior and also my good Sister Dr.A. LAVANYA, MD (S), 
for her suggestions and valuable knowledge throughout my dissertation work, no word to 
express my thanks.  
I am thankful to COLLEAGUES AND JUNIORS also my CLASSMATES of 
Sirappu Maruthuvam Department, Chennai for their support to complete my dissertation 
work. 
 
 
 
 
     CONTENTS     
S.NO                                       TITLE PAGE.NO 
1.  INTRODUCTION 1 
2.  AIM & OBJECTIVES 3 
3.  REVIEW OF LITERATURES  
 3.1 SIDDHA ASPECT OF DISEASE  4 
3.2 MODERN APECT OF DISEASE  23 
3.3 DRUG REVIEW INTERNAL   
39 
3.4 DRUG REVIEW EXTERNAL 46 
3.5 VARMAM REVIEW 63 
4.  MATERIALS AND METHODS  
 4.1 PURIFICATION OF THE DRUG INTERNAL 74 
4.2 PREPARATION  OF THE DRUG INTERNAL  77 
4.3 PREPARATION OF THE DRUG EXTERNAL  78 
4.4 STANDARDIZATION OF THE DRUG (PPC)  
 4.4.1 TRADITIONAL WAY TO TESTING 81 
4.4.2 PHYSICO – CHEMICAL ANALYSIS 81 
4.4.3 HEAVY METAL ANALYSIS 83 
4.5 TOXICOLOGICAL STUDY  
 4.5.1 ACUTE TOXICITY STUDY 84 
4.5.2 REPEATED 28 DAYS ORAL TOXICITY STUDY 89 
4.6 PHARMACOLOGICAL TUDY  
 4.6.1 ANALGESIC ACTIVITY 92 
4.6.2 ANTI – INFLAMMATORY ACTIVITY 92 
4.7 CLINICAL STUDY 93 
5.  RESULTS AND OBSERVATIONS 103 
6.  DISCUSSION  154 
7.  SUMMARY 158 
8.  CONCLUSION 159 
9.  BIBLIOGRAPHY 160 
10.  ANNEXURES  
I N T R O D U T I O N S  | 1 
 
1. INTRODUTION 
Siddha system of  Medicine is the citadel  of medical system. It is used not 
only to cure but also to prevent disease and in turn to increase the lifespan of human 
beings. The word Siddha not only denote simplicity, uniqueness, ancient nobility, 
truth and purity but includes all these sense and stands a unique lofty entity. It was 
propound by lord Siva as a scientific and spiritual benevolence to his disciples. The 
system was woven into discipline of reputation by symphony of eighteen siddhars. 
             Siddhars   have all along been considered to be a mystical and mysterious sect 
and a complex phenomenon in the history. Siddhars were of the concept that a healthy 
soul can only be developed through a healthy body. So they developed methods and 
medication , that are believed to strengthen their physical body and thereby their 
souls. The aforesaid eighteen siddhars practiced various arts in Siddha medicine 
again this had resulted in alchemy meant for the preparation of acting potent high tech 
medicine for the treatment of incurable disease. 
Varma medicine is the unique pride of Siddha medical System. Varmam is a  
energy point  that functions in the body. Diseases can be treated using Varma. Varma 
is a specialized field of Siddha pertained to cure neurological weakness, 
neuromuscular problems Its is height efficacy, instant and quick relief, low adverse 
effect. 
Siddhi refer to a yogic state .Siddhars are said to be the yogis having lived a 
complete life, 
                                 “Mulamathai arinthakal  yogamachu muraimaiyudan 
Kandakkal vadhamachu 
                                    Salamudan kandavaranum vasamay niruppar 
                                                Sathirathai sutterithal avane Siddhan
1” 
-Saint Agathiyar 
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In Siddha system of medicine the total number of diseases are classified to be 
4448 types.  But the sub classification methodology and enumeration differ from one 
source to another. However, the classification of the majority of these diseases is 
either based on clinical symptoms or vitiation of humor.  Further they have been sub-
classified on the basis of Mukkutram and the predominant symptoms, affected organs 
and etiological factors.  As per Yugi text, the sings and symptoms of Thandagavatham  
may be correlated with Lumbar Spondylosis in modern science. 
 
Lumbar spondylosis is an age related degenerative condition affecting the 
lower region of spine. In patients with lumbar spondylosis, the spine will be 
compressed and the space between the vertebrae will be narrowed. Symptoms vary 
from Low back Pain, radiating pain, numbness, muscle weakness etc depending on 
the severity of the disease 
 
        In clinical practice considerable number of cases of Thandagavatham are 
Reported daily. Hence selected the disease Thandagavatham (Lymbar Spondylosis)  
for my clinical study with  Naga Chenduram (Internal Medicine) mentioned in 
Aathma  Ratchamirutham  Sindhu which is indicated for Vatha diseases,  Moolayoga 
Nirkundi  Thylam (External medicine) mentioned in  Theraiyar Thailavarkam which 
is also indicated for Vatha diseases and Varmam theraphy for thandaga vatham.  
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                                             2. AIMS AND OBJECTIVES 
2.1 AIM: 
To compare the therapeutic efficacy of Siddha herbo mineral trial drug Naga 
Chendhuram (Internal Medicine)   Moolayoga  Nirkundi  Thailam (External 
Medicine) and  Varmam  Therapy (External Therapy) derived from classical Siddha 
literature and  Its synergistic effects in Management of  “Thandaga Vatham” (Lumbar 
Spondylosis). 
2.2 OBJECTIVES: 
1. PRIMARY OBJECTIVES: 
 To evaluate the therapeutic efficacy of “NAGA CHENDHURAM” (INT)    
“MOOLAYOGA NIRKUNDI THAILAM” (EXT) and “VARMAM  
THERAPY” on “THANDAGA VATHAM” (Lumbar Spondylosis). 
2. SECONDARY OBJECTIVES: 
 To collect the authorial measures and literature reveiws of 
Thandagavatham in ancient Siddha and Modern Literatures. 
 To evaluate the Safety of the trial drug NAGA CHENDURAM 
(Internal). 
 To standardize the preparation of selected trail drug.  
 To use modern parameters to conform the diagnosis of the disease. 
 To discuss the various literature evidences for clinical features of 
Thandaga Vatham in Siddha medicine and Lumbar Spondylosis in 
modern science. 
 To explore the traditional preparation with scientific evaluation of trail 
drug. 
 To study the effect of Varmam in Thandagavatham patients. 
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3. REVIEW OF LITERATURES 
3.1 SIDDHA  LITERATURE REVIEW: 
 Siddha system surmise that the human body is composed of  96 thathuvam and 
72000 blood  vessles and nerves beyond  these, there are 10 naadi, 10 vaayu, and 14 
vegangal. All of them play vital roles in various functions of the body. That 10 Naadi 
further divided into 3 humors i.e Vatham,  Pitham, Kabam and these are also called as 
Uyir Thathu  which is most important for the formation and maintenance of the body. 
These humors remain in the balanced state in normal healthy person and disturbance 
in their equilibrium leads to ill health. 
„„ந஥ோய்஥ோடி ந஥ோய்முத ஦ோடி னதுதணிக்கும் 
                யோய்஥ோடி யோய்ப்஧ச் செனல்2’’ 
 
So for 4448 diseases are classified by Agasthiyar Rathina Surukkam Naadi, 
and in this  Vatha diseases are classified as 84 types. According to Yugimuni Vadha 
disease are 80 in numbers. Vadha disease are otherwise called as Valli Noi. 
As per the siddhar Theraiyar‟s concept  normal complexion or the shine of the 
skin is altered due to derangement in Vatham humour or Vali humour. 
                                   „„யோதந஬ோது நந஦ிசெடோது2’’  
3.1.1VATHAM: 
 Vaatham is Formed by Aakasam
2
 and Vayu, controls the nervous action that 
constitute movement, activity, sensation, etc. Vatham predominates in the bone. It is 
responsible for the production  implementation of thoughts to action. Generally, its 
function is more related to cerebral activities like, thinking and action.  
 Vatham predominates in first one third of life when activity, growth ,sharpness 
of function of sense, are greater 
 However Vadham represents Vayu, Mind, Dryness, Pain, Flatulence, 
Sensitive, Lightness  
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யாதத்தின் இருப்஧ிடம் 
          ‘‘஥ோசநன்஫ யோதத்துக் ெிம௅ப்஧ிடநந நெ஭ோய் 
             ஥ோடிக்குக் ெீசமன்று ஥யி஬஬ோகும்3’’    
 
VATHAM GENERALLY LIVES IN: 
ய஭ிமுத஬ோ சனண்ணினமுக் குற்஫ சநல்஬ோம் 
       யோழ்யசதனும் நதெமுற்றும் ஧ம்஧ிப் ஧பந்து 
 சத஭ிவு஫ச் ெோற்றும்஥ோ஧ிக் குக்ெீழ் யோதம் 
       தீனின்கூ ஫ோநமந஬ோ உந்தி னோயிக்4 
                                       (நம௅த்துயத் த஦ிப் ஧ோடல்) 
The seat of Vadham is below the naval 
1. Hip region 
2. Bones  
3. Joints  
4. Nerves  
5. Muscles  
6. Skin  
7. Hair follicles 
8. Abanan 
9. Edakalai 
10. Below the umbilicus  
11. Stools 
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QUALITIES OF VATHAM: 
‚ய஭ினின் ஧ண்பு ந஥கிழ்ச்சி ஧பயல் 
       ய஫ட்சி யிரபதல் தட்஧ம் நுட்஧ம் 
அ஭ிக்கும்஧ித்தத் தரநந்த குணங்கள் 
     அ஦ற்஫ல் ந஥ாய்ரந ஥ீர்ரந-ந஥ய்ரந‛4 
Own qualities are 6 in numbers 
1. Dry 
2. Cold 
3. Subtle 
4. Rough 
5. Unstable 
6. Light 
NATURAL PROPERTIES OF VATHAM: 
 Giving briskness 
 Respiration 
 Functioning the mind, thoughts and body 
 Regulation of fourteen physiological  reflexes 
 Uniform functioning of the seven elements  
 Strengthening the five sensory organs     
FUNCTION OF VADHAM: 
 Improves the sensory organs 
 Improves speech 
 Stabilizes the mind 
 Given more enthusiasm 
 Control respiration 
 Pass out 14 naturals 
 
REVIEW OF LITERATURES | 7 
 
KINDS OF VATHAM:  
  “முற஫றநனோம் ஧ிபோணந஦ோட஧ோ஦ன் யினோ஦ன் 
    மூர்க்ெநோ முதோ஦ச஦ோடு ெநோ஦ ஦ோென் 
   தி஫றநனோங் கூர்நந஦ோடு ெிம௅ெ பன்஫ோன் 
     நதயதத்த ச஦ோடுத஦ஞ்ெனனு நோகும்3” 
                          (ம௄ெி றயத்தின ெிந்தோநணி 800) 
10 DIFFERENT KINDS OF VATHAM: 
             Even though the vatham seems to be the same, it has got ten different forms 
and actions. The five important forms of Vaatham among ten.  
VATHAM COLOUR GOD 
Praanan 
(Uyirkal) 
Air of life Blue Moon 
Abaanan downward motion (Flatus Air) Green Varadharajar 
Vyaanan 
(Paravukal) 
spreads throughout Milky white Eman 
Udhaanan 
(Melnokkukkal) 
upward motion Ligthening Fire 
Samaanan 
(Nadukkal) 
upward and downward motion Topaz Sun 
Naagam higher intellectual function Gold Ananthan 
Koorman 
yawning 
 
 Vishnu 
Kirukaran Salivation Black Shiva 
Devathatthan Laziness Crystal Devendran 
Dhananjayan That acts on death Blue Dhanwantari 
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 Praanan 
 Praanaa, literally the “forward moving air,” moves inward and governs   
reception  of all  types  from the eating of food, drinking of water, and inhalation of 
air, to the reception of  sensory impressions and mental experiences. It is propulsive in 
nature, setting things in motion and guiding them. It provides the basic energy that 
drives us in life. 
 
Apanan 
 Apanan, literally the „„air that moves away‟‟ moves downward and outward 
and governs all forms of elimination and reproduction . It govers the elimination of 
the stool and the urine, the expelling of semen, menstrual fluid and the fetus and  on 
deep level it rules the elimination of negative sensory, emotional and mentam 
experiences. It is the basis of our immune function on all levels   
 
Udanan 
Udanan, literally the “upward moving air,” moves upward and qualitative or 
transformative movements of the life-energy. It governs growth of the body, the 
ability to stand, speech, effort, enthusiasm and will. It is our main positive energy in 
life through which we can develop our different bodies and evolve in consciousness. 
 
Samanan 
Samanan, literally the “balancing air,” moves from the periphery to the center, 
through a churning and discerning action. It aids in digestion on all levels. It works in 
the gastrointestinal tract to digest food, in the lungs to digest air or absorb oxygen, 
and in the mind to homogenize and digest experience, whether sensory, emotional or 
mental. In doing so it assists all the other Pranas in their work. 
 
Vyanan 
Vyanan, literally the “outward moving air,” moves from the centre to the 
periphery. It governs circulation on all levels. It moves the food, water and oxygen 
throughout the body, and keeps our emotions and thoughts circulating in the mind, 
imparting movement and providing strength 
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3.1.2 VADHA NOI: (5) 
 
DEFINITION: (IYAL) 
 Vadha is the principle of motion in the body and mind. When Vadham is   
healthy, the movement of the body are graceful, unimpeded and yet controlled. When 
out of balance the movements become erratic, excessive, decreased, or blocked and 
manifest the clinical symptoms of pricking pain, stabbing pain, and severe pain and at 
lost, paralysis may occur 
 
Symptoms manifested due to raise of Vadham and cause Vadha disease.  In vadha 
diseases, the one and more symptoms can be seen. 
 
1. Having Astringest taste in the mouth 
2. Thirst 
3. Dryness 
4. Constipation 
5. Blackish discoloration of skin, eyes and faces 
6. Numbness 
7. Pain 
8. Rigidity 
9. Lack of movements 
10. Internal bone pain 
11. Inflammation of joints 
12. Paralysis of limbs 
 
AETIOLOGY OF VATHA DISEASES: 
According to Yugi Vaithya Chinthamani 
"஋ன்஦நய யோதந்தோ ச஦ண்஧ தோகும் 
நிகுத்திந஬ ந஦ிதர்ெல௃க் செய்து நோறு 
஧ின்஦நய ச஧ோந்தற஦நன நெோபஞ் செய்து 
ச஧ரிநனோர்ெள் ஧ிபோநணறபத் தூஷ் ணித்தும் 
யன்஦நய யச்செோத்திற் நெோபஞ் செய்து 
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              நோதோ஧ிதோ கும௅றய ந஫ந்து ந஧ர்க்கும் 
ென்஦நய நயதத்றத ஥ிந்றதசெய்த ந஧ர்க்குங் 
ெோனத்திற் ெ஬ந்திடுநந யோதந் தோந஦” 
"தோச஦ன்஫ ெெப்ந஧ோடு துயர்ப்பு றபப்பு 
ெோதெநோய் நிஞ்சுெினுஞ் ெறநத்த யன்஦ம் 
ஆச஦ன்஫ யோ஫ி஦து ச஧ோெித்த ஬ோலும் 
ஆெோத் நத஫஬து குடித்த ஬ோலும் 
஧ோச஦ன்஫ ஧ெலு஫க்ெ நிபோயி மிப்பு 
஧ட்டி஦ிநன நிெவுறுதல் ஧ோப சநய்தல் 
நதச஦ன்஫ சநோமினோற் நநற் ெிந்றத னோெில் 
ெீக்ெிபநோய் யோதநது செ஦ிக்குந் தோந஦” 
 
"ஆணோ஦ யபன்஫ச஦ௌநன நதினோ நோந்தர் 
அெதி஧ப நதெினர்ெட் ென்஦ நீனோர் 
஧ோச஦ன்஫ ஧ெலு஫க்ெ நிபோயி மிப்பு 
஧ட்டி஦ிநன நிெவும௅தல் ஧ோப சநய்தல் 
நெோ஦ோ஦ குபசநோமிறன ந஫ந்த ந஧ர்ெள் 
செோற஬ெ஭வு ச஧ோய்ெோநங் கு஫ித்த ந஧ர்க்கு 
ஊ஦ோ஦ ெடந்தன்஦ில் யோதம் யந்து 
உற்஧யிக்கும் நயதத்தி லுண்றந தோந஦.3" 
According to the text, those who disrespect the parents, teachers, insulting the 
elders,   blaspheming the Holy books - having cruel in their thoughts daytime sleep 
and sleeplessness at night will get Vatha diseases. Increased intake of bitter taste, 
astringent, sour  foods, increased intake of cold water, excessive starvation, Sexual 
indulgence will produce Vatha diseases. 
 
As per konganavar  Vathakaviyam 
“ஆச்ெப்஧ோ னிதன்கூற஫ ஥஬தோய்ச்செோன்ந஦ோம் 
       ஆெோெோ னிந்த௄ல்தோன் ெோயினெோண்டத்தில் 
யோச்ெப்஧ோ யோதத்தின் கூற஫ச்செோன்ந஦ோம் 
       யோதநதின் யோம௃஥ிற஬ நனங்ெிப்ந஧ோகும் 
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ெோச்ெப்஧ோ ெ஬ங்ெினது தினங்ெிப்ந஧ோகும் 
       ெண்ந஦ிநன யதுக்குநத்தி஧ந்தோன் நெல௃ 
நோச்ெப்஧ோ நக்ெி஦ிதோன் நதுநயோசடோக்ெ 
       நோர்க்ெநதோய் கூடியிற஭ னோடும்஧ோநப5” 
 
According to the text ‘Pararasasekaram’ 
‚சதோமில்ச஧ோறுறெப்புக்ெோர்த் தல்துயர்த்தல் யிஞ்சுெினுஞ்நெோறும் 
஧றமனதோம் யபகு நற்ற஫ப் ற஧ந்திற஦ னம௅ந்தி ஦ோலும் 
஋மில்ச஧஫ப் ஧ெலு ஫ங்ெி இபயி஦ி லு஫ங்ெோ தோலும் 
நறம஥ிெர் கும஬ி ஦ோந஭ யோதங்நெோ ஧ிக்குங் ெோநண‛ 
 
‚ெோணநய நிெவுண் டோலுங் ெம௅து஧ட் டி஦ியிட் டோ 
நோ஦ற஦ னோர்ெண் நநோெ ந஫க்ெினு நிகுந்திட்டோலும் 
ஆணய ந஬ங்ெ டம்றந னங்ஙந஦ யிடோத தோலும் 
யோனுதன் நட஥ல் ஬ோந஭ யோதங்நெோ ஧ிக்குங் ெோநண‛  
 
‚஧ோரி஦ிற் ஧னப்஧ட்டோலும் ஧஬ம௅டன் நெோ஧ித் தோலும் 
ெோசப஦க் ெம௅ெி நனோடிக் ெழுநபத் துபத்தி ணோலும் 
஌ர்ச஧று த஦து ச஥ஞ்ெின் நிெத்துக்ெ நறடந்திட்டோலும் 
஧ோரினெோற்஫ி ஦ோல௃ம் ஧டரினும் யோதங் ெோணும்‛ 
 
‚ெோ஬ங்ெண் நோ஫ி ம௃ண்ணுங் ெோரினத் தோலுந் தண்ணரீ் 
ெோ஬நய னம௅ந்தி ணலுஞ் ெந்தினி லுட்ெோர்ந் தோலும் 
நெோ஬நோம் பு஭ிப்பு ச஥ய்றநக் குற஫ய஫ யம௅ந்தி ஦ோலும் 
யோ஬யோர் முற஬஥ல் ஬ோந஭யோதமுற் ஧யிக்குங் ெோநண‛ 
 
‚உற்஧யித் சதழுநப் ந஧ோநத ம௃னர்பு஫த் துடிறனப் ஧ற்஫ித் 
சதற்஧஫க் குறடந்து ந஥ோவுஞ் செய்துநந஬ ந஥ோக்கு நோெில் 
யிற்ச஧ோ஬ி த௃த஬ி ஦ோந஭ நந஬ிடுங் குணங்ெ டம்நில் 
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செோற்ச஧று யோதம் நதோன்றுசநன் ஫஫ிந்து செோள்ெ‛ 
 
‚சதரிந்துமுன் செோன்஦ யண்ணஞ் செய்னெோ ஬டிறனப் ஧ற்஫ி 
நோந்தற஦ப் ந஧ோற்஫ி நிர்த்து நற்றுநநல் ந஥ோக்கு நோெில் 
அபன்஫ற஦த் துதினோ நோந்த பனுெரிக் ெின்஫ நெோனில்  
ெரிந்திடுங் கும஬ோய் யோதங் குடிபுகுஞ் ெோற்றுங் ெோந஬6‛ 
 
The  lines indicate that  intake of acrid, bitter, pungent content foods, intake of 
grains, sleep in day time and instead loss of sleep in night time. Increased intake of 
food, frequent exposure to starvation, sexual indulgence, increased fear, increased 
anger, increased sadness, and higher exposure to air, changes in taking of diet timings 
will produce Vatha diseases. 
According to the text ‘Angaathipaatham’ 
"ெோ஦றடனோ஬ச் ெத்தோற் ெடும்஧ெி னோற்நெோ ஧த்தோல் 
ஊ஦நி ஬ிபயில் யோர்த்றத ம௃பம்ச஧஫ யிறபக்ெ ஬ோலூண் 
ஆ஦஧ின் மு஦ியோல் நோம௅ தடுத்தடுத் துறபக்குஞ் செோல்஬ோல் 
ஈ஦நி ஬ிெழ்ச்ெி னோ஦ யிெல்யோத நெோ஧ங் ெோணும்7. 
Excessive hunger and increased anger will   produce Vatha disease. 
According to the text Sarabenthirar Vaithiya Muraigal- Vatha Rokha Sikitchai 
 Consuming low quantity of food 
 Sexual indulgence 
 Decreased sleep 
 Excessive purgation or emesis. 
 Excessive loss of blood during blood letting theraphy. 
 Doing heavy work 
 Control of reflexes like faeces,urination 
 Conversion of undigested food juices into toxic substances(aamam) 
 Trauma 
 Control of hunger 
 Injuries in uyirnilaigal 
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                 All these activities leads to the low level of saaram in ducts.  So as to 
compensate this more of vaayu‟s were produced and affect one or more organs. 
GENERAL CHARACTERS OF VATHA DISEASES: 
    “யோதம் யந்துற்஫ ந஧ோது யனி஫து ச஧ோம௅நிக் செோள்ல௃ம் 
      தோதயிழ்ந்திடுப்பு றெெோல் ெந்துெள் ெடுப்பு நதோன்றும் 
      ெீசதோம௅ ந஬மு ஥ீம௅ந் ெிறுத்துடன் ெடுத்து யிம 
      நோதயநறப நநல் யந்த யோதத்தின் குணநிதோநந8.” 
           -  Yugi Munivar Perunool Kaaviyam     
         Vatha diseases are characterized by pain and swelling in joints, abdominal 
distension, constipation and burning micturition. 
       “காணப்஧ா யாதநீ஫ில் கால்ரககள் ந஧ாருத்து ந஥ாவும் 
 னணப்஧ா குடல் புபட்டும் ந஬ச஬ம் ந஧ாருநி கட்டும் 
ஊணப்஧ா கு஭ிருங் காய்ச்சல் உடம்ந஧ல்஬ாம் குத்து யாய்வு 
யணீப்஧ா குதநிறுக்கும் யினர்ரயயும் நயர்க்கும் தாந஦9.” 
          -  Agathiyar Vaithiya Kaaviyam -1500 
 Joint pain, nausea, constipation, oliguria, fever, rigor and sweating are 
produced due to vitiated vatham. 
 
"யோதயறீு அன்஦நி஫ங்ெோது ெடுப்புண்டோம்யண்ணமுண்டோம் 
நநோதுெட்டு சபோெம் சுபமுண்டோ நிம௅நலுநோ மு஫ங்ெோநதன்றும் 
ஓது சூரின யோத ந஦஬ோகு ஥டுக்ெ முண்டோம் ந஧ோம௅ள்ெ஭ோய்த் 
தீத஦நய ஥பம்஧ிெித்து ெந்துெள் நதோறுங் ெடுக்கும் தி஦முந்தோந஦10" 
                             - Thaerayar Vaagadam 
     
 Loss of appetite, pain and redness, fever, cough, insomnia, shivering, pain in 
all joints is the characteristic features of vatha diseases, which is mentioned in 
Theraiyar Vaagadam. 
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FACTORS THAT INFLUENCE THE VATHA DISEASE: 
A)Seasons which deranges Vatham : 
 In Muthuvenil kaalam, the solar radiation increases the evaporation of water 
content from the earth in turn produces dryness. Similarly the dryness is produced in 
our body and causes vatha diseases. 
B)Diets which deranges Vatham: 
 According to the text ‘Sababathi Kaiyedu’ 
      "ய஭ி தம௅ ெோய்ெிமங்கு யறபயி஬ோ தநி஬ல் நெோறம 
        பு஭ி தனிர் ந஧ோன்நிகுக்கு முற஫னி஬ோ வுண்டி நெோடல் 
        கு஭ிர்தம௅ ய஭ினிற் ந஫ெங் கு஦ிப்பு஫ வு஬யல் ச஧ண்டிர் 
        கு஭ிதம௅ நனக்ெம் ச஧ற்ந஫ோர் ெடிசெனல் ெம௅யினோநல்11." 
 
              Excessive intake of tubers food items, irregularity in taking foods, taking 
curd, acrid food items, higher exposure to wind, living in higher attitudes, sexual 
indulgence, and increased exposure to chill weather will aggravate Vatha diseases. 
 
C) Habitual characters which deranges Vatham: 
 InTheraiyar vagadam it is said as, 
“நயய்னி஬ில் ஥டக்ரகனாலும் நிகத்தண்ணரீ் குடிக்ரகனாலும் 
 நசய்னிரம நக஭ி஦ரபச் நசர்ந்தனு஧ யிக்ரகனாலும் 
 ர஧னந஦ உண்ரநனாலும் ஧ாகற்காய் தின்ரகனாலும் 
 ரதனந஬ யாதநபாகம் ச஦ிக்குநநன் ஫஫ிந்து நகாள்ந஭11.” 
             Walking in hot climate, excessive intake of water, sexual indulgence, intake 
of bitter guard will leads to Vatha diseases. 
 
REVIEW OF LITERATURES | 15 
 
In Aaviyalikkum Amuthamurai Surukkam 
 “செோல்஬நய யோதநது நீ஫ிற்஫ோ஦ோல் 
      நெோர்யறடந்து யோம௃யோல் நதெசநங்கும் 
 சநல்஬நய றெெோல்ெ஭ெதி ம௃ண்டோம் 
     சநய் முடங்கும் ஥ிநிப சயண்ணோ திநிம௅ண்டோகும் 
 சயல்஬நய வுடல் ச஧ோம௅மும் யனிம௅ற஭க்கும் 
      யிம௅ம்஧ி னன்஦ஞ் செல்஬ோது யிந்து஥ட்டம் 
 செோல்஬நய ஥ோப்பு஭ிக்கும் ெமிச்ெல் உண்டோகும் 
       கூ஫ி஦ோர் நற஬னமு஦ி கூ஫ி஦ோநப12” 
 
 Pricking  sensation all over the body  
 Pain all over the joints 
 Difficulty in flexion and extension  
 Nausea  
 Loss of appetite  
 Constipation  
 Incontinence of urine  
 Diarrhea   
CLINICAL FEATURES: 
According to Yugi Vaithiya Chinthamani the following clinical features were 
seen:  
 Stiffness of the body 
 Sweating 
  Body pain 
 Paleness of the body 
 Yellowish discolouration of stools and urine. 
CLASSIFICATION OF VATHA DISEASE: 
In Yugi Vaithiya Chinthamani Perunool-800 described 80 types of Vatha disease 
   ‘‘஋ன்஦நய யோதநது ஋ண்஧தோகும் 
 ஌ற்஫நோம் ந஧ம௅றடன சயமிற஬க் நெ஭ோன8’’ 
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3.1.3 THANDAGAVATHAM: 
             In Yugi Vaithya Chinthaamani, Yugi munivar has classified the Vatha 
diseases as 80 types and “Thandagavatham” is one among them. In Yugi as per the 
text the signs and symptoms of Thandagavatham may be correlated with the Lumbar 
Spondylosis in Modern science 
 அயனங்ெற஭ச் சென஬஫ச் செய்து உடம்ற஧த் 
தண்டத்றதப் ந஧ோல் யழீ்த்தி, ஥ீட்டல், நடக்ெல் அறெத்தல் 
முத஬ினறய இல்஬ோநல் ெயத்றதப் ந஧ோல் ெிடக்ெச் செய்ம௃ம் ஒர் 
யறெ யோத ந஥ோய். 
 Thandagavatham is a kind of rheumatic disorder characterized by great 
prostration in which the body is rendered like a log of wood, unable to stretch or fold 
the limbs and pass motion or urine.  
தண்டெயோதம் = தண்டெம் +   யோதம் 
தண்டெத்றத ஧ோதிக்கும் யோதம். 
            தண்டெம்- யணீோதண்டம் ஋ன்னும் முதுசெலும்பு 
 (Vertebral column with spinal cord as the seat connecting mystic centres) 
நதெ யிற஫ப்பு – Stiffness of the whole body, which is rigid and stiff like a rod. 
 Vatham - is a clinical condition characterized by pain, swelling, pricking 
sensation and loss of function due to vitiated Vatham, which is the principal humour 
of the body
13
.                                                                        
                                                                  - T.V. Sambasivam Pillai Dictionary 
தண்டக யாதம் 
யழுத்தநய   மூ஬ோதோ   பத்றத   ஧ற்஫ி  
             நம௅யிநன   நநந஬஫ி   முதுகு   நட்டோய் 
யிழுத்தநய   ெிபெில்   யந்து   யினர்வு   நோெி 
              யிகுயோெ    ந஥ோயோெி    நந஦ி   ென்஫ிப் 
஧ழுத்தநய    ம௃டம்ச஧ங்கும்  ஧ஞ்சு   ந஧ோ஬ோகும் 
               ஧ோங்ெோ஦    ந஬ெ஬மு   நஞ்ெ    ஭ோகும் 
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குழுத்தநய  தண்டெநோம்  யோதந்  தன்ற஦க் 
       கூ஫ிந஦ோங்  குணசந஬ோம் கூர்ந்து ஧ோநப   
   
கூர்ந்திட்ட  ந஬ெங்ெள் துரிதநோ஦ோல் 
      செோண்டடக்ெிப்  ஧ின்புதோன் செோடிதோய்த் தள்஭ி 
ஊர்ந்திட்ட  ெரிபத்தி  லுதிப  நீ஫ி 
             உ஫த்நதய்த்துத் தற஬னத஦ி ச஬ண்சணய் யோர்க்ெில் 
யோர்ந்திட்ட  யமி஥டக்ெில்  சநத்த  யந்தோன் 
யோதந்தோ  னுற்஧யித்து  ஥றடசெோடோநல் 
஥ோர்ந்திட்ட  ஥பம்ந஧ோடு  ஋லும்஧ிற்  சூழ்ந்து 
      ஥னுெிநன  நனோடிச஥ஞ்ெி  ந஬றுந்தோந஦3 
                           
                           -ம௄ெி  றயத்தின ெிந்தோநணி  800  
 
ந஥ாய் யரும் யமி: 
 முதுகுத் தண்டின் ெீழ்பு஫நிம௅ந்து தற஬யறபனிலும்                
ெி஭ம்஧ின  யோம௃யி஦ோல் ஌ற்஧டும்  
 தற஬னில் ஧ோபம் சுநதல்  
கு஫ிகுணங்கள்: 
 உடல் இறுகுதல்            - Stiffness  
 உடல் ய஬ித்தல்             - Pain  
 உடல் ஧ழுத்து ஧ஞ்சு ந஧ோல் சயல௃த்தல்      - Anemia 
 தற஬ முழுெல்,அதிெ தூபம் ஥ட்த்தல் முத஬ினயற்஫ோல் 
ய஭ிகுற்஫ம் நீண்டும் அதிெரித்து ஥பம்பு ஋லும்புெற஭  
஧ற்஫ி சூழ்ந்து ஥டக்ெ முடினநல் செய்து அவ்யோம௃ 
ச஥ஞ்சுயறபனிற் ஧ோம௃ம்3  
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In the text, Vatha Noi Maruthuvam: 
     "தண்டுயோதத்தின் குணத்றத ெோற்஫க்நெ஭ோய் நடநனிந஬ 
      ஧ண்நடதண்டுநிெஊதி ஧ற்஫ிச஧ோம௅நி செோண்டிம௅க்கும் 
      யிண்நடோம்ெி஬ ந஧ோதுற஭வுண்டோம் நிகுந்த யோட்டமுண்டோம் 
      செோண்சட ந஦மும் த஭ர்ச்ெிம௃ம் நெோ஧நதிெம் ெோணும் ஋ன்ந஫14." 
          
- Vatha Noi Maruthuvam.  
 There will be inflammation of spine. Generalized tiredness, mental depression 
and excessive anger. 
இடுப்பு யாதம் 
      "இடுப்஧து ெடுத்து உற஭ந்து இறடயிடோ ய஬ித்துக் செோள்ல௃ம் 
         முடுக்ெநோய் கு஦ினநய தோன் முடுெிநன ஥ிநிபசயோட்டோது 
       துடுக்செ஦ யந்து அடம௅ந சுபநது அற்஧ம் அற்஧ம் 
         ெடக்செ஦ இடுப்ற஧ச் சுற்஫ி ெோர்ந்திடும் யோதம்தோந஦ 
       ஥டப்ச஧஦ந஧ோது சநத்த ஥ய்னநய ய஬ிக்குசநன்஦ 
         செடப்ந஧஦ந஧ோதும் ெற்ந஫ குணசந஦ நதோன்றுநோெில் 
       ஧டுப்ச஧஦ ந஧ோதும் னோநம் ஧ோெினோல் யோதமுண்டோம் 
          இடுப்ச஧஦ நெம௅ம் யோதத்தின஬ிது ஋ண்ணுயநீப14" 
                                                                          - Vatha Noi Maruthuvam 
The clinical features are:- 
 Continuous pain in the low back region. 
 Difficulty in bending forward and standing erect from that position. 
 Sudden onset of fever. 
 Warmth around the low back region. 
 Pain increases on walking and decreases on lying.   
3.1.4 SIDDHA PATHOPHYSIOLOGY: 
 Changes in lifestyle, occupation, food and other habits lead to development of 
this disease by causing derangement of Muththathu. Improper food habits alter the 
elemental composition directly while the other causes lead to derangement of these 
elements indirectly. When the elemental composition is altered, the Uyir Thaathukkal 
or the three humours which are made up of these elements naturally also get 
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deranged. This simultaneously leads to derangement of seven Udal Thaathukkal, 
which produces symptoms of the disease „Thandagavatham‟. 
DIAGNOSIS 
 Diagnosis of Thandagavatham in Siddha is based on Envagai Thervugal and 
also on the other factors like 
1. Uyirthaathukkal  
2. Udalthaathukkal 
3. Gnanenthiriyam 
4. Kanmenthiriyam   
THREE UYIR THAATHUKKAL 
1. Vatham 
 In Thandagavatham patients among the ten types of vatham; the following two 
types are affected and causing symptoms accordingly. 
1. Viyaanan - Affected (producing restriction of joint movements) 
2. Samaanan - Affected (deranging the other four types of vatham) 
2. Piththam 
   Among the Five types of pitham (Analaagam, Ranjagam, Pirasagam, 
Alosagam and Saathagam) the Saathaga piththam only affected in Thandagavatham 
patients and causing difficulty in walking, sitting and bending forward postures. 
3. Kabam 
 In the five types of Kabam (Avalambagam, Kilethagam, Pothagam, 
Tharpagam and Santhigam) Avalambagam and Santhigam affected in 
Thandagavatham patients and causing pain in low back region and restriction of 
movements in the lumbo sacral junctions. 
SEVEN UDAL THAATHUKKAL: 
 Among the seven Udal Thaathukkal (Saaram, Senneer, Oon, Kozhuppu, Enbu, 
Moolai and Chukkilam / Suronitham) the following four are commonly affected in 
Thandagavatham patients. 
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1. Saaram - Tiredness and weakness 
2. Oon- Muscular pain, muscle spasm 
3. Kozhuppu - Pain in low back region, restriction of movements. 
4. Enbu - Weakness of bone 
GNANENTHIRIYAM 
 The Thandagavatham patients are having the clinical features of pain, numbness 
and burning sensation especially in lower limbs. These are felt through Mei. 
KANMENTHIRIYAM 
   In Thandagavatham patients, Kaal is affected. This is due to radiating pain, 
difficulty in walking etc.  
NOI KANIPPU VIVADHAM (DIFFERENTIAL DIAGNOSIS) 
Some types of Vatha diseases are mimicking like Thandagavatham. Careful 
and clear history taking and examination will reveal the correct diagnosis. 
They are:     1. Aasuvathamba vatham.   2. Ooruthamba vatham. 
 
3.1.6 MANAGEMENT: 
In Siddha system of Medicine, the line of treatment plays an important role in  
the normalization of  Thirithosam. In Siddha system, the treatment is based on 
mukkutram theory.  The main goal of the treatment was not only healing the disease 
but also the prevention  of disease  and rejuvenation of  udalkattugal. 
In Thandagavatham Usually Vitiated vatha humour is to be normalised.  
Detoxification of the body, Rejuvenation and Toning the spine is done with 
appropriate Internal Medicines. During the External Therapy, Special Varma massage 
with Medicated Oil, Steam bath, Pizhichil or Oil immersion technique and other 
physical manipulating techniques are used to relieve spasms, inflammatory changes, 
nerve compressions and strengthening the spine. 
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INTERNAL MEDICINE:  NAGA CHENDHURAM, 65 mg with honey twice 
daily, after food for the period of 48 days. 
EXTERNAL MEDICINE:   MOOLAYOGA NIRKUNDI THYLAM with 
VARMAM therapy. 
 
DIETARY REGIMENS: 
According to ‘Siddha Maruthuvanga Churukkam 
    செங்ெழு ஥ீர்நெோஷ்டந் நதன்நி஭கு ஥ல்ச஬ண்சணய் 
    தங்குச஧ம௅ங் ெோனந் தழுதோறம- ஋ங்செங்கும் 
    கூட்டுெிறு முத்துச஥ய் நெோதில் உழுந்திறயெள் 
    யோட்டுந஦ி ஬த்றத நதி15 
1. Senkazhuneer 
2. Koshtam  
3. Honey 
4. Pepper 
5. Gingely oil 
6. Perungaayam  
7. Thazhuthaazaai 
8. Castor oil 
9. Black gram 
These were the food items for the Vatha patients. 
Tender vegetables: 
 Avarai (Dolichos lablab) 
 Aththi (Ficus racemosus) 
 Murunkai (Moringa oleifera) 
 SunMullangi (Raphanus sativus) 
 Thoothuvelai (Solanum trilobatum) 
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 Pirandai (Cissus quadrangularis) 
 Karunai kizhangu (Colocasia antiquarum)  
 Kathiri (Solanum melongena) 
             Greens: 
 Sirukeerai (Amaranthus tricolor) 
 Mookkurattai (Boerrhavia diffusa) 
 Puliyaarai (Hibiscus cannabinus) 
 Ponnankanni (Alternanthera sessili) 
 Manali (Gisekia pharanaceoides) 
 Mudakkaruththaan (Cardiospermum halicacabum) 
Pulses:  
 Ulunthu (Vigna mungo) 
 Pottukkadalai fried (Cajanus cajan) 
Dairy products: 
 Cow‟s milk, buttermilk      
AVOID: 
 Tubers except karunai kizhangu(Colocasia antiquorum) 
 Maaporulghal(Carbohydrates) 
 Vaazhai(tender Musa paradisiaca) 
 Kaaramani(Vigna unguiculata) 
 Verkkadalai(Arachis hypogea) 
 Pattaani(Pisum sativum) 
 Mochai(Lablab purpureus) 
 Kezhvaragu(Eleusine coracana) 
 Kambu(Pennisetum typhoideum) 
 Solum(Sorghum vulgare) 
 Sour,astringent foods 
 
OTHER ADVICES:  
 Activities involving excessive use of joints were identified and avoided. 
 Brief period of rest for involvement of joints 
 Regular exercises. 
 Avoid exposure to chilled air. 
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                             3.2 MODERN ASPECT OF DISEASE 
                  
   Low back ache is a very common problem and has a ubiquitous distribution. 
Among the galaxy of causative factors both spinal and extra spinal, the common cause 
for low backache is the lumbar disc disease. Bad posture plays a very significant role in 
the genesis of  this disease
16
. 
3.2.1 Lumbar Spine: 
The lumbar spine refers to the lower back, where the spine curves inward towards the 
abdomen. It starts about five or six inches below the shoulder blades, and connects with the 
thoracic spine at the top and extends downward to the sacral spine. 
              
                                                   
 
 
 
 
 
 
Fig 3.2.2 
The lumbar spine consists of 5 moveable vertebrae numbered L1-L5. The 
complex anatomy of the lumbar spine is a remarkable combination of these strong 
vertebrae, multiple bony elements linked by joint capsules, and flexible 
ligaments/tendons, large muscles, and highly sensitive nerves. It also has a complicated 
innervation and vascular supply. 
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The lumbar spine is designed to be incredibly strong, protecting the highly 
sensitive spinal cord and spinal nerve roots. At the same time, it is highly flexible, 
providing for mobility in many different planes including flexion, extension, side 
bending, and rotation. 
 
TACKLING THE TERMINOLOGY: 
Lumbar is derived from the Latin word "lumbus," meaning lion, and the lumbar spine 
earns its name. It is built for both power and flexibility - lifting, twisting, and bending. 
ANATOMY: 
The lumbar vertebrae are five lumbar vertebrae of which the first four are typical 
and the fifth is atypical. A lumbar vertbra different from other vertebrae one is large size 
and other one is  the absence of costal facets on the body. 
The lumbar vertebrae, numbered L1-L5, have a vertical height that is less than 
their horizontal diameter. They are composed of the following 3 functional parts: 
1. The vertebral body, designed to bear weight 
2. The vertebral (neural) arch, designed to protect the neural elements 
3. The bony processes (spinous and transverse), which function to increase the 
efficiency of muscle action 
The lumbar vertebral bodies (vertebrae) are the heaviest components, connected 
together by the intervertebral discs. The size of the vertebral body increases from L1 to 
L5, indicative of the increasing loads that each lower lumbar vertebra absorbs. Of note, 
the L5 vertebra has the heaviest body, smallest spinous process, and thickest transverse 
process. 
The intervertebral discal surface of an adult vertebra contains a ring of cortical bone 
peripherally termed the epiphysial ring. This ring acts as a growth zone in the young 
while anchoring the attachment of the annular fibers in adults. A hyaline cartilage plate 
lies within the confines of this epiphysial ring. 
The figure on the left depicts the general characteristics of the first through fourth 
lumbar vertebrae. The fifth vertebra contains certain peculiarities, which are detailed 
below. 
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Anatomy of Lumbar  vertebrae:
18
 
A. Body  
B. Arch is composed of  pedicles - 2,  
C. Laminae - 2 ,   
D. Different bony processes (1 spinous, 4 articular, 2 transverse),  
E. Joined together by facet joints and ligaments. 
F. Vertebral foraman 
 
The figure on the below depicts the general characteristics of the first through fourth 
lumbar vertebrae. The fifth vertebra contains certain peculiarities. 
 
                                               Fig 3.2.2 
Lumbar vertebral joints: 
There are two types of joint in the lumbar spine. Both of these articulations are 
not unique to the lumbar vertebrae, and are present throughout the vertebral column. 
 
A. symphyseal joints: 
The mobility of the vertebral column is provided by the symphyseal joints between 
the vertebral bodies, formed by a layer of hyaline cartilage on each vertebral body and an 
intervertebral disc between the layers. 
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B. Synovial joints 
The synovial joints between the superior and inferior articular processes on 
adjacent vertebrae are termed the facet joints (also known as zygapophysial joints or Z-
joints ). The facet joints have been described as finger-like, and they link the vertebrae 
together. The facet joints are located at the posterior area of the spinal column. They 
permit simple gliding movements. The movement of the lumbar spine is largely confined 
to flexion and extension with a minor degree of rotation (see the image below). The 
region between the superior articular process and the lamina is the pars interarticularis. A 
spondylolysis occurs if ossification of the pars interarticularis fails to occur. 
 
Lumbar intervertebral discs
19
 
                 
                                                  Fig 3.2.3 
 
Discs form the main connection between vertebrae. They bear loading during 
axial compression and allow movement between the vertebrae. Their size varies 
depending on the adjacent vertebrae size and comprises approximately one quarter the 
length of the vertebral column. Each disc consists of the nucleus pulposus, a central but 
slightly posterior mucoid substance embedded with reticular and collagenous fibers, 
surrounded by the annulus fibrosus, a fibrocartilaginous lamina.  
The annulus fibrosus can be divided into the outermost, middle, and innermost 
fibers. The anterior fibers are strengthened by the powerful anterior longitudinal ligament 
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(ALL). The posterior longitudinal ligament (PLL) affords only weak midline 
reinforcement, especially at L4-5 and L5-S1, as it is a narrow structure attached to the 
annulus. The anterior and middle fibers of the annulus are most numerous anteriorly and 
laterally but deficient posteriorly, where most of the fibers are attached to the cartilage 
plate. 
 
NATURAL HISTORY OF LUMBAR DISC DISEASE
16
 
       Degenerative process is divided into three stages 
 
 1 .Stage of dysfunction 
 Seen between 15 and 45 years of age 
 Circumferential and radial tears are seen in the disc annulous 
 Localized synovitis of the facet joints is seen 
 2. Stage of instability 
o Seen between 35 and 75 years of age. 
o There is an internal disruption of the disc. 
o Progressive disc resorption takes place. 
o Degeneration of facet joints with lax capsules, subluxation and joints 
erosion are seen. 
 3. Stage of stabilization  
o Seen over 60 years of age 
o Progressive development of hypertrophic bone about the disc and facet 
joints  leading  to segmental stiffening or frank ankyloses is seen.  
o Disc herniation is considered as a complication of disc  degeneration  in 
stages II and I.Spinal stenosis is a complication in late instability and early 
stabilization stages. Disc can  herniate either into the body as Schmorl’s 
node or posteriorly towards the canal compressing the nerve roots 
LUMBAR VERTEBRAL LIGAMENTS: 
The joints of the lumbar vertebrae are supported by several ligaments. They can 
be divided into two groups; those present throughout the vertebral column, and those 
unique to the lumbar spine. 
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Present throughout Vertebral Column 
 Anterior and posterior longitudinal ligaments: Long ligaments that run the 
length of the vertebral column, covering the vertebral bodies and 
intervertebral discs. 
 Ligamentum flavum: Connects the laminae of adjacent vertebrae. 
 Interspinous ligament: Connects the spinous processes of adjacent vertebrae. 
 Supraspinous ligament: Connects the tips of adjacent spinous processes. 
 
                                                          Fig .3.2.4 
 
 
 
 
 
Unique to Lumbar Spine: 
The lumbosacral joint (between L5 and S1 vertebrae) is strengthened by 
the iliolumbar ligaments. These are fan-like ligaments radiating from the transverse 
processes of the L5 vertebra to the ilia of the pelvis 
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                                               Fig 3.2.5 
LUMBAR SPINE MUSCULATURE: 
Four functional groups of muscles govern the lumbar spine and can be divided 
into extensors, flexors, lateral flexors, and rotators. Synergistic muscle action from both 
the left and right side muscle groups exist during flexion and extension of the Lumbar 
spine.  
      
                  
                                                                   Fig 3.2.6 
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S.NO  LUMBAR MUSCLES FUNCTION NERVE 
1. PSOAS MAJOR Flexes thigh athip joint 
& vertebral column 
L2 , L3  sometimes 
L1 or L4 
2. INTERTRANSVERSARII 
LATERALIS 
Lateral flextion of 
vertebral column 
Ventral primary 
division of spinal 
nerve 
3. QUADRATUS LUMBORUM  Lateral flextion of 
vertebral column 
T12, L1 
4. INTERSPINALES Extends vertebral 
column 
Dorsal primary 
divisions of spinal 
nerves 
5. INTERTRANSVERSARII 
MEDIALES 
Lateral flextion of 
vertebral column 
Dorsal primary 
divisions of spinal 
nerves 
6. MULTIFIDUS Extends & rotates 
vertebral column 
Dorsal primary 
divisions of spinal 
nerves 
SPINAL CURVES: 
When viewed from the side, an adult spine has a natural S-shaped curve. The 
lower spine curves slightly inward, toward the abdomen. This inward curve of the spine is 
called lordosis. The curves work like a coiled spring to absorb shock, maintain balance, 
and allow range of motion throughout the spinal column. 
RISK FACTORS 
Jobs requiring heavy and repetitive weightlifting 
Operation of motor vehicles 
Cigarette smokers and tobacco consumers 
Women with greater number of pregnancies. 
Obesity and other cardiovascular risk factors. 
Monotonous work, working overtime, etc.. 
Improper postural habits.  
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3.2.2 LUMBAR SPONDYLOSIS: 
Low back ache is a very common problem and has a ubiquitous distribution. 
Among  the  galaxy of causative  factors both spinal and extra spinal, the common cause 
of low backache seems to be the lumbar disc disease. Bad posture plays a very significant 
role in the genesis of  this disease.
16 
This is a degenerative disorder of the lumbar spine characterised clinically by an 
insidious onset of pain and stiffness and radiologically by osteophyte formation.
17 
Spondylosis, noninflammatory degenerative disease of the spine resulting in 
abnormal bone development around the vertebrae and reduced mobility of the 
intervertebral joints. It is primarily a condition of age and occurs much more commonly 
in men than in women; onset of symptoms is gradual, but untreated spondylosis will 
progress to disabling tingling pain, limited motion, and partial paralysis in affected areas 
of the body. The high incidence of simultaneous degenerative changes to the 
intervertebral disc, vertebral body
30
 
 
SYNONYMS:  
1.Lumbar arthrosis, 
2.Lumbar spondylitis, 
3.Hypertrophic arthritis  
4.Osteoarthritis of lumbar spine. 
 
TACKLING THE TERMINOLOGY
20
: 
The terms lumbar osteoarthritis, disk degeneration, degenerative disk disease, and 
spondylosis are used in the literature to describe anatomical changes to the vertebral 
bodies and intervertebral disk spaces that may be associated with clinical pain syndromes. 
 
EPIDEMIOLOGY 
20
: 
Lumbar spondylosis is present in 27-37% of the asymptomatic population. In the 
United States, more than 80% of individuals older than 40 years have lumbar 
spondylosis, increasing from 3% of individuals aged 20-29 years.  
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Internationally, lumbar spondylosis can begin in persons as young as 20 years. It    
increases with, and perhaps is an inevitable concomitant of, age.  
Approximately 84% of men and 74% of women have vertebral osteophytes, most 
frequently at T9-T10 and L3 levels. Approximately 30% of men and 28% of women aged 
55-64 years have lumbar osteophytes. Sex ratio reports have been variable but are 
essentially equal. Spinal osteophytosis in postmenopausal Japanese women correlated 
with the CC genotype of the transforming growth factor ß1  gene. 
CAUSE: 
Lumbar spondylosis appears to be a nonspecific aging phenomenon. Most studies 
suggest no relationship to lifestyle, height, weight, body mass, physical activity, cigarette 
and alcohol consumption, or reproductive history.  Spondylosis, or age-related changes in 
your spinal bones and other tissues, is a common condition that affects most of  us at 
some point in our lives.   
1.Bad posture and chronic back strain is the commonest cause.  
2.Other causes are, previous injury to the spine, 
3.previous disease of the spine, birth defects and old intervertebral disc prolapse. 
Over time, the changes of spondylosis can put pressure on spinal nerves where 
they join the spine (nerve roots). In advanced cases, bones, discs or other tissues can 
press on the spinal cord. 
The major risk factor for spondylosis is aging. By age 60, most people have signs 
of lumbar spondylosis that can be seen on an X-ray. Other risk factors for spondylosis 
are:   
 Past neck injury (often several years before)  
 Severe arthritis  
 Past spine surgery  
 Being over 40 is a risk factor for lumbar spondylosis. 
 
PATHOGENESIS
20
: 
The high incidence of simultaneous degenerative changes to the intervertebral 
disk, vertebral body, and associated joints suggests a progressive and dynamic 
mechanism, with interdependent changes occurring secondary to disk space narrowing. 
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Intervertebral disks are believed to undergo what Kirkaldy Willis and Bernard 
first coined a “degenerative cascade” of three overlapping phases that may occur over the 
course of decades
32
.  
Phase I (Dysfunction Phase)   
The initial effects of repetitive microtrauma with the development of 
circumferential painful tears of the outer, innervated anulus, and associated end-plate 
separation that may compromise disk nutritional supply and waste removal. Such tears 
may coalesce to become radial tears, more prone to protrusion, and impact the disk’s 
capacity to maintain water, resulting in desiccation and reduced disk height. Fissures may 
become ingrown by vascular tissue and nerve endings, increasing innervation and the 
disk’s capacity for pain signal transmission.  
Phase II (Instability Phase)  
This is characterized by the loss of mechanical integrity, with progressive disk 
changes of resorption, internal disruption, and additional annular tears, combined with 
further facet degeneration that may induce subluxation and instability.  
Phase III (Stabilization Phase),  
Continued disk space narrowing and fibrosis occurs along with the formation of 
osteophytes and transdiscal bridging. 
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Biochemical research exploring osteophyte formation supports the above process. 
Osteophyte lipping is believed to form at periosteum through the proliferation of 
peripheral articular cartilage which subsequently undergoes endochondral calcification  
and ossification. Changing weight mechanics and pressure forces as well as 
alterations in oxygen tension and dynamic fluid pressure appear to be influential factors 
in osteophyte formation. Mesenchymal stem cells of the synovium or periostium are 
likely precursors, with synovial macrophages and a milieu of growth factors and 
extracellular matrix molecules acting as probable mediators in this process. 
 
CLINICAL FEATURES: 
LOW BACKACHE: 
 Back pain is common in the second decade, disc disease and disc herniation in the 
third and fourth decade. 
 
RADICULOPATHY:  
 This refers to pain in the distribution of the sciatic nerve and is invariably due to 
disc herniation. This is called Sciatica. 
NERVE ROOT COMPRESSION: 
 About 95 % of the disc prolapse takes place through the L4-L5 region 
compressing the L5 nerve root. 
 
RADIOGRAPHY  
 X ray for back is not very reliable as normal findings are observed in 7-46% of 
the cases.  Disc space is reduced in old cases 
 
ETIOLOGY/RISK FACTORS:
20
 
What factors mediate this degenerative progression what leads a large portion of 
the population to manifest spondylosis, even early on in their lives? Given the substantial 
variability in the number and degree of spine changes observed in individuals and the 
wide range of clinical presentations, answers to these questions hold promise to broaden 
treatment options. 
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The inﬂuence of age 
Large studies of osteoarthritis have long recognized the aging process to be the 
strongest risk factor for bony degeneration, particularly within the spine. An extensive 
autopsy study in 1926 reported evidence of spondylitis deformans to increase in a linear 
fashion from 0% to 72% between the ages of 39 and 70 years. A subsequent autopsy 
study by Miller et al. similarly noted an increase in disk degeneration from 16% at age 20  
to about 98% at age 70 years based on macroscopic disk degeneration grades of 600 
specimens. Other studies corroborate  this ﬁnding. 
The associations are never the less imperfect. Kramer found increasing age to be 
signiﬁcantly associated with osteophyte formation but not predictive of the degree of disk 
space narrowing observed in a retrospective review of radiographs of women. She 
observed signiﬁcant variability, noting “although few younger women have high average 
scores, some older women have no radiographic sign of OA, while others are severely 
affected.” Multiple studies have also demonstrated the presence of signiﬁcant lumbar 
degeneration to be evident even within the ﬁrst two decades such variability within 
members of the same age category suggests the inﬂuence of other contributing factors. 
  
The impact of activity and occupation 
Disk generation has long been associated with certain activities. Retrospective 
studies cite Body Mass Index (BMI), incident back trauma, daily spine loading (twisting, 
lifting, bending, and sustained nonneutral postures), and whole body vibration (such as 
vehicular driving) to be factors which increase both the likelihood and severity of 
spondylosis .While these correlations exist, a study following progressive radiographic 
changes in lumber DDD did not ﬁnd signiﬁcant associations with the extent of physical 
activity, noting only age, back pain, and associated hip OA to be predictive of DDD and 
osteophyte changes. 
 
DIAGNOSIS: 
 A diagnostic approach the initial evaluation for patients with low back pain begins 
with an accurate history and thorough physical exam with appropriate provocative 
testing
34
. 
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SCIATIC  NERVE STRETCH TEST:  Patient is in supine position ,one of the leg is 
raised with one hand, ipsilateral knee is pressed over by other hand. This test produce 
tension in the hamstring muscles which in turn compresses the sciatic nerve and produces 
pain. 
 
BREGARD’S TEST: After doing SLRT, dorsiflex the foot. This further tension on the 
sciatic nerve and the patient complains of  pain. 
 
LASEGUE’S TEST: Here the hip is flexed, knee is flexed and the leg is slowly 
straightened. 
 
BIICKLING’S SIGN: Perform as SLRT until the patient complaints of pain. Now ask 
the patient to flex the knee.  Pain decreases due to relief of tension on the nerve. 
 
SICARD’S TEST: After doing SLRT, dorsiflex the great toe. This puts further tension 
on the sciatic nerve and the patient complains of the pain. 
 
FAJERSZTAJN’S TEST: After doing SLRT, dorsiflex the foot. This tenses the sciatic 
nerve and the patient complains of the pain. 
 
WEEL LEG RAISIN TEST: Here, the patient is asked to perform SLRT of the normal 
limb. If the patient complains of   pain on the affected side, then it is highly suggestive of 
disc prolapse and this is a pathognomonic test which has more relevance then the 
conventional SLRT. 
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BILATERAL STRAIGHT LEG RAISING TEST: Here, patient is asked to raise both 
the legs simultaneously. This is a test for the sacroiliac joint rather than the spine. During 
the first 70 degree, stress is on the SI joint, over 70 degree stress is on the lumbar spine. 
 
FEMORAL NERVE STRETCH TEST (REVERSE SLRT): Here, the patient is in 
prone position and is asked to lift the leg straight. This puts a stretch on the femoral 
nerve. If the patient complains of the pain it indicates high level disc prolapse (L1-L2-L3). 
 
INVESTIGATIONS :  
Diagnosis is mainly based on X-rays 
1. X- Ray Lumbar Spine  
 AP view –       look for vertebral column, any pedicular lesion. 
 Lateral view – shape & size of vertebral body. 
                 Oblique view–  side to side collapse, Inter vertebral disc space    
2. Computed Tomography(CT): 
            It is useful in non invasive painless outpatient procedure. It gives a cross sectional 
study of the pathology.  CT helps to detect the foraminal structures and lateral disc 
prolapse. 
3. MRI  
MRI helps to detect intra-spinal lesion, examine entire spine, identifies 
degenerative disc. 
4. Myelograph 
 Consists of injecting radio opaque dye (myodil was used earlier now it is the water 
soluble iopamiro300, which is being used) into the spinal canal and taking radio graphs 
of the back  
5. Other Tests: Discography, Bone scans, EMG 
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DIFFERENTIAL DIAGNOSIS 
1. Multiple myelomas  
2. Extra dural tumors. 
              3.  Peripheral neuropathy 
              4.  Herpes zoster 
              5.  Multiple sclerosis   
              6.  Ankylosing spondylitis 
              7. Vascular insufficiency 
              8. Osteoporosis with stress fractures 
  
COMPLICATIONS  
 Severe spinal stenosis 
 Paraplegia 
 Cauda equina syndrome 
 Neurogenic  claudication. 
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DRUG REVIEW OF SIDDHA ASPECT- INTERNAL 
3.3 INTERNALMEDICINE: NAGA CHENDHURAM
12 
INGREDIENT 
INTERNAL DRUG: NAGA CHENDHURAM 
INGREDIENTS
22
: 
1. Nagam  (Zinc)                              
2. Manosilai(Red Orpiment)                                                                                             
3. Soodham(Mercury)                            
4. Veeram (Hydrargyrum per chloride)                                                              
5. Gandhagam (Sulphur)        
6. Ilupai nei (Oil of Madhuga longifolia) 
7. Venkolinchi ver (Baptisia bracfeata )                  
8. Potralai kayanthagarai (Eclipta prostrata )  
NAGAM (zincum) 
஥ாகம் ப஧ாதுகுணம் 
“மநகங் கிளர்ம஧தி பவட்டைனழடைத் தணிக்கும் 
மவகங் கிபாணி விைக்குங்காண் – ம஧ாகாப் 
஧ரினமுடளப் புண்டண ஧னித்தினத்டதப் ம஧ாக்கும் 
அரினதுத்த ஥ாக் நது35” 
PROPERTIES OF NAGAM : 
1 Taste  Thuvarppu. 
2 Actions Astringent, Haemostatic, Alterative. 
3 Types Perugan nagam, Sirugan nagam 
4 Uses Veneral diseases, Pitha noi, Diarrhoea 
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RASAM (HYDRARGYRUM)     
                                         பசம் ப஧ாதுகுணம்                                                                                 
               “஬ி஫ிந஢ோய் கி஧ந்஡ிகுன்஥ம் ம஥ய்ச்சூலன புண்குட்                                  
                    ட஫ிகோனில் ஬ிந்து஬ிணோல் அத்ல஡ – ஬஫ி஦ோய்                                  
                 புரியு ஬ி஡ி ஦ோது புரி஦ிநணோ ம஦ல்னோம் 
                     இரியு஬ி஡ி ஦ோது ஥ில்லன36.” 
  
PROPERTIES OF RASAM:  
                                          PROPERTIES OF RASAM 
1 It is under Panchasudham 
2 Best quality Mercury obtained from cinnabar is considered 
as pure and suitable for medical purpose. 
3 Taste Six testes present, Dominant is sweat 
4 Potency Thatpam and veppam 
5 Actions Tonic, Alterative, purgative, Diuretic, Anti 
septic 
6 Types Rasam, Rasendhiran, Sootham, Misaragam, 
Baaratham. 
 
7 Uses Eye diseases, Veneral diseases, Hanson’s 
diseases, and Ulcer and skin diseases. 
8 Toxicity symptoms Loosening of teeth, Ascities, Deafness, 
Bleeding disorder. 
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GANTHAGAM (SULPHUR) 
 
        “ம஢ல்னிக்கோய்க் கந்஡ிக்கு ஢ீள்த஡ிமணண் குட்ட஥ந்஡ம் 
         ஬ல்லன க஬ிலைகுன்஥ ஬ோயுகண்ந஠ோய் – மதோல்னோ 
         ஬ிடக்கடி஬ன் ந஥கந஢ோய் ஬றீுசு஧ம் நத஡ி 
         ஡ிடக்கி஧சு ஠கீதம்நதோணந் ந஡ர்37.” 
ARTIFICIAL PREPARATION OF GANTHAGAM: 
             
              ப஥ல்ைிக்காய் பகந்தக டவப்பு 
கண்டுதோர் ம஢ல்னிக்கோய் மகந்஡கத்ல஡ 
கட்டோக ல஬ப்த஡ற்கு ஬லகல஦க்நகளு 
஥ண்டனந஥ ஦ோணோக்கோல் ம஦டுத்துப்தோரு 
஬ோகோண ம஢ல்னிக்கோய் நதோனோம் தோந஧38.” 
PROPERTIES OF GANTHAGAM: 
                             TABLE4: PROPERTIES OF GANTHAGAM 
1 Taste Kaippu, Thuvarppu. 
2 Actions Astringent, Laxative, Alterative, 
Insecticide 
3 Types White, Red, Golden, Black colour 
4 Uses 18 types of skin diseases, liver 
enlargement, leprosy, eczema.  
5 Excretion excreted through sweat, milk, urine 
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MANOSILAI (ARSENIC BI SULPHIDE
22
) 
                                    நம஦ாசிடை ப஧ாதுகுணம் 
       “மகோடி஦ குஷ்டம் கோய்ச்ைல் ஢டுக்கனஜ கல்னி஦ில஧ப் 
        புச்ைினந்஡ிப் நதைறு஥ நணோைிலனக்குப் நதசு.” 
 
ARTIFICIAL PREPARATION OF MANOSILAI: 
                   
                         நம஦ாசிடை டவப்பு 
஢ோடும்தோர் ஥நணோைிலன஦ின் ல஬ப்புக்நகளு 
       ஢ன஥ோண அரி஡ோ஧ம் தனந்஡ோமணோன்று 
 . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . 
கூடும்தோர் ம஬ள்லப஦து ஢ிநந்஡ோணப்தோ 
          கூர்ந்துைி஬ப் தோ஦ிருக்கும் உள்நப஡ோநண39.” 
      
PROPERTIES OF MANOSILAI: 
 
                      TABLE6: PROPERTIES OF MANOSILAI
22 
 
1 Actions Alterative, Febrifuge, Tonic,  
2 Types Two types Natural and Artificial 
3 Uses Chronic skin diseases, leprosy, 
Intermittent fever, Ajakalliga rogam, 
Asthma, Insect bites. 
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Veeram: 
                   ப஧ாதுகுணம் 
குன்஥ம஥ோடு குட்டங் மகோடி஦஬ணி னத்஡ி஧டு 
துன்஥ோங் கிைப்மதருக்கஞ் சூலனந஢ோய்- ஬ன்ல஥யுறு 
கோ஥ி஦ப்புண் ஠ோ஡ி஦ந஢ோய் கண்டோற்ைவ் 
஬஧ீமணனுஞ் ைோ஥ி஢ோ ஥த்ல஡யுச் ைரி40 
 
1.  It is under Panchasudham 
2.  Taste Bitter  
3.  Potency  Veppam 
4.  Actions  Alterative, Anti septic 
5.  Uses Gastric ulcer, leprosy, severe vadha diseases, 
throbbing pain associated diseases, venereal 
diseases, bubo in the groins occurs to the 
females and males, various types of eye 
diseases. 
6.  Toxicity symptoms Sweeling  in Mouth to GIT, Drooping of 
saliava, Dysphagia. 
 
REVIEW OF LITERATURES |  
 
44 
ILUPAI NEI (OIL OF MADHUGA LONGIFOLIA): 
                                          
                   இலுப்லத ம஢ய் மதோதுகு஠ம் 
“க஧ப்தோ ணடருங் கடிைி஧ங்கு புண்னும் 
உ஧ப்தோ ஥ிடப்பு஬னி ந஦ோடுங்-க஧ப்தோன் 
தோகும஥ோ஫ி ஥ோந஡! தனமுண்டோந் துற்தனம் 
ஏ஡கு஥ி லுப்லத஦ி மணய்க் நக41.” 
GENERAL PROPERTIES OF ILUPAI NEI 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots 
SUB CLASS Asterids 
ORDER Ericales 
FAMILY Sapotaceae 
GENUS Madhuca 
SPECIES M. longifolia 
BOTANICALNAME  Madhuga longifolia 
ENGLISH NAME South Indian mahua  
PARTS USED Oil 
CHEMICAL 
CONSTITUENT  
madhucic acid (penta cyclic triterpenoids), 
madhushazone,  oleanane type triterpene glycosides and 
madhucosides A and B, Sapogenin, triterpenoids, 
steroids, saponin, flavonoids and glycosides 
ACTION Anthelmintic, Anti pyritic. 
 SUVAI-THANMAI-
PIRIVU 
thuvarppu– thatpam – Karppu 
USES Oil used as Emollient, Skin Disease, Rheumatism, 
Headache, laxative, Piles, Hemorrhoids, Emetics, Anti 
Earth worm.. 
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POTRALAI KAYANTHAGARAI (ECLIPTA PROSTRATA ): 
                         
஡ிருவுண்டோம் ஞோணத் ம஡பிவுண்டோ ந஥லன 
஦ருவுண்டோ முள்பம஡ல்னோ முண்டோங்  குருவுண்டோம் 
மதோன்ணோகத் ஡ன்ணோகம் மதோற்நலனக்லக ஦ோந்஡கல஧த் 
஡ன்ணோகத் ஡ின்நோகத் ஡ோன்41 
                                                                                    ந஡஧ன் ம஬ண்தோ 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots 
SUB CLASS Asterids 
ORDER Asterides 
FAMILY Asteraceae  
GENUS Eclipta  
SPECIES E. prostrate 
BOTANICALNAME  Eclipta prostrata  
ENGLISH NAME Trailing eclipta 
PARTS USED Hole plant 
CHEMICAL 
CONSTITUENT  
madhucic acid (penta cyclic triterpenoids), 
madhushazone,  oleanane type triterpene glycosides 
and madhucosides A and B, Sapogenin, 
triterpenoids, steroids, saponin, flavonoids and 
glycosides 
ACTION Cholagogue, Tonic, Alterative, Ement, Purgative, 
Deobstruent, Hepictonic. 
 
SUVAI-THANMAI-
PIRIVU 
Thuvarppu– Vetpam  – Karppu 
USES Eye disease, ulcer. 
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DRUG REVIEW OF SIDDHA ASPECT 
EXTERNAL MEDICINE: MOOLAYOGA NIRKUNDI THAILAM   
                                             INGREDIENTS
23 
GROUP I  
Vennochi (Vitex negundo)  
Amanukku (Ricinus communis) 
Erukku (Calotropis gigantea) 
Amukkura (Withania sominifera) 
Pungu (Butea frodosa) 
Paruvagai (Mimosa sirissa)                                   
Athondai (Capparis zelanica) 
Peramutty (Pavonia odorata) 
Punarmurugai (butea monosperma) 
Kuthiraivali (Echinochloa frumentacea) 
Ailamaram (Chukrasia tabulais)    
GROUP II  
Thevatharu (cedrus deodara) 
Sukku (zingiber officinale) 
Ulunthu (vigna munga)   
Mavilinga pattai (Crateava mangna)                       
Kunkiliyam (vatria indica)                                                                                                                        
       Sithiramulam (plumbago indica)       
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VENNOCHI (VITEX NEGUNDO): 
                             
“ந஢ோ஦ோ கனில஦ ம஢ோடிக்கு பருந்஡ம஬ம்ல஥ 
ந஦ோ஦ோ ஥஠ோளு மு஦ர்த்து஡லுக்- கோ஦ 
஬ந்஡மு஡ல் ஢ண்தோகி ஬ோ஡த்ல஡ ந஦யுற்஬ோற் 
ைிந்து஬ோ ஧ங்கணலுந் ஡ீ”42 
GENERAL PROPERTIES: 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Asteroids  
ORDER Lamiales  
FAMILY Lamiaceae  
GENUS Vitex  
SPECIES V . negundo 
BOTANICALNAME  Vitex negundo  
ENGLISH NAME  Five leafs chaste tree 
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
 Casticin, Isoorientin, Chrysophenol D, Luteolin, P–
hydroxybenzoic acid and D-fructose. 
ACTION Febrifuge ,Expectorant, Diuretic.  
 SUVAI-THANMAI-
PIRIVU 
Kaippu, Thuvarppu – Veppam – Karppu 
USES Roots and leaves are used in eczema, ringworm and 
other skin diseases, liver disorders,spleen enlargement, 
rheumatic pain, gout, abscess, backache. 
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 AMANUKKU (RICINUS COMMUNIS): 
 
GENERAL PROPERTIES: 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids  
ORDER Malpighiales  
FAMILY Euphorbiaceae   
GENUS Ricinus  
SPECIES R .communis 
BOTANICALNAME  Ricinus communis  
ENGLISH NAME  Castor –oil plant 
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
 Ricinine, Quercetin 3-O- -rutinoside (rutin), 
Terpenoids, Tocopherol  
ACTION Antivatha, Analgesic , Anti-inflammatory.  
 SUVAI-THANMAI-
PIRIVU 
Kaippu – Veppam – Karppu 
USES Skin diseases, Dysponea, Hydrocele, Flatulance, 
Piles, Cough, Head ache, Leprosy, Arthrities, 
Calculus, Dysuria, Fever, Swelling, Mental 
diseases, Painful Micturation. 
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ERUKKU (CALOTROPIS GIGANTEA) : 
 
GENERAL PROPERTIES: 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Asteroids  
ORDER Gentianales   
FAMILY Apocynaceae    
GENUS Calotropis   
SPECIES C. gigantean 
BOTANICALNAME  Calotropis gigantea 
ENGLISH NAME  Gigantic swallow wort 
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
 Calotoxin, Calactin, Uscharin.  
ACTION Anthelmentic, Alterative, Laxative, Stimulant.  
 
SUVAI-THANMAI-
PIRIVU 
Kaippu, Karam, Mathuram – Veppam – Karppu 
USES Useful in cough, cold and constipation. 
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AMUKKURA (WITHANIA SOMINIFERA): 
 
“மகோஞ்ைத் து஬ர்ப்தோங் மகோடி஦க஦ம் சூலன஦ரி 
஥ிஞ்சுக஧ப் தோன்தோண்டு ம஬ப்த஡ப்பு- ஬ிஞ்ைி 
முசுவுறு ந஡ோடமும்நதோ ந஥ோகம்அண லுண்டோம் 
அசு஬கந் ஡ிக்மகன் நநி44” 
GENERAL PROPERTIES: 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Asterids  
ORDER Solanales   
FAMILY Solanaceae    
GENUS Withania   
SPECIES W. somnifera 
BOTANICALNAME  Withinia somnifera 
ENGLISH NAME  Winter cherry 
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
  Withanolides,Somniferine, Perinponyine  
ACTION Febrifuge, Diuretic, Alterative, Aphrodisiac, 
Deobsturent.  
 SUVAI-THANMAI-
PIRIVU 
Kaippu, Karam, Mathuram – Veppam – Karppu 
USES Ashwagandha is applied to the skin for treating 
wounds, backache, and one-sided paralysis 
(hemiplegia). 
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PUNGU (BUTEA FRODOSA): 
 
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids 
ORDER Fabales  
FAMILY Fabaceae 
GENUS Butea 
SPECIES B. frodosa  
BOTANICALNAME  Butea frodosa 
ENGLISH NAME  Winter cherry 
PARTS USED Root  
ACTION Febrifuge, Diuretic, Alterative, 
Aphrodisiac,Deobsturent.  
 
SUVAI-THANMAI-
PIRIVU 
Kaippu, Karam, Mathuram – Veppam 
– Karppu 
REVIEW OF LITERATURES |  
 
52 
PARUVAGAI (MIMOSA SIRISSA): 
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids 
ORDER Fabales  
FAMILY Fabaceae 
GENUS Albisia  
SPECIES B. lebbeck 
BOTANICALNAME Mimosa sirissa  
ENGLISH NAME Winter cherry 
PARTS USED Root  
ACTION Astringent, Refrigerant 
 
SUVAI-THANMAI-
PIRIVU 
Kaippu, Karam, Mathuram – Veppam 
– Karppu 
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ATHONDAI (CAPPARIS ZELANICA): 
 
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids 
ORDER Brassicales 
FAMILY Capparaceae  
GENUS Capparis  
SPECIES c.zeylanica  
BOTANICALNAME  Capparis zeylanica 
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
  Thioglucosides, Glucocapparin, N-tricontane, α-and 
β-amyrin,  Alkaloid, a phytosterol, a Mucilaginous 
substance and a water-soluble acid, capric acid. The 
seeds contain fixed oilthioglucosides, glucocapparin, 
n-tricontane, α-and β-amyrin, an alkaloid, a 
phytosterol, a mucilaginous substance and a water-
soluble acid, capric acid. The seeds contain fixed oil 
ACTION Sedative, Stomachic.  
 
SUVAI-THANMAI-
PIRIVU 
Kaippu – Veppam – Karppu 
USES Root bark is sedative, cooling, cholagogue, stomachic and 
antihidrotic; along with spirit given in cholera.Root bark 
is sedative, cooling, cholagogue, stomachic and 
antihidrotic; along with spirit given in cholera. 
 
REVIEW OF LITERATURES |  
 
54 
PERAMUTTY (PAVONIA ODORATA): 
 
 
 
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids 
ORDER Malvales  
FAMILY Malvaceae  
GENUS Pavoni  
SPECIES P . odorata  
BOTANICALNAME  Pavonia odorata  
PARTS USED Root  
ACTION Cooling, Carminative, Diuretic, 
Diaphoretic 
SUVAI-THANMAI-
PIRIVU 
Thuvarppu – Veppam – Karppu 
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KUTHIRAIVALI (ECHINOCHLOA FRUMENTACEA): 
 
 
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Monocots 
SUB CLASS Commelinids  
ORDER Poalea  
FAMILY Poaceae  
GENUS Echinochloa  
SPECIES E . frumentacea 
BOTANICALNAME  Echinochloa frumentacea 
PARTS USED Seeds  
USES The plant is useful in the treatment of 
biliousness and constipation 
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AILAMARAM (CHUKRASIA TABULAIS) :  
 
      
                      
 
 
 
 
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids 
ORDER Sapindales  
FAMILY Mekiaceae  
GENUS Chukrasia  
SPECIES c.tubulais  
BOTANICALNAME  Chukrasia tabulais 
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
 contains sitosterol, melianone, scopoletin, 6,7-
dimethoxycoumarin, tetranorterpenes and tabularin. 
ACTION Counter irritant, febrifuge.  
 
SUVAI-THANMAI-
PIRIVU 
Kaippu – Veppam – Karppu 
USES An extract of the bark has powerful astringent 
properties and has been used to treat diarrhoea and 
as a febrifuge 
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THEVATHARU (CEDRUS DEODARA): 
 
      
                            
 
 
 
 
 
 
KINGDOM Plantae 
DIVISION Pinophyta  
CLASS Pinopsida  
ORDER Pinales  
FAMILY Pinzceae  
GENUS Cedrus  
SPECIES C . deodara 
BOTANICALNAME  Cedrus deodara 
PARTS USED bark  
CHEMICAL 
CONSTITUENT  
contains cedeodarin (6methyltaxifolin), dihydr
omyricetin (ampelopsin), cedrin (6methyldihy
dromyricetin), cedrinoside
[17]
 and deodarin 
ACTION Astringent, febrifuge.  
 
SUVAI-THANMAI-
PIRIVU 
Thuvarpu, Kaippu – Veppam – Karppu 
USES An extract of the bark has powerful astringent 
properties and has been used to treat 
diarrhoea and as a febrifuge 
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SUKKU (ZINGIBER OFFICINALE): 
                        
  
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Monocots  
SUB CLASS Commelinids  
ORDER Zingiberales   
FAMILY Zingiberaceae   
GENUS Zingiber   
SPECIES Z . offcinale  
BOTANICALNAME Zingiber officinale  
PARTS USED Root  
CHEMICAL 
CONSTITUENT  
 zingerone, shogaols and gingerols with       
[6]-gingerol(1-[4'-hydroxy-3'-methoxyphenyl]-
5-hydroxy-3-decanone 
ACTION Stimulant, Stomachic,Carminative.  
 
SUVAI-THANMAI-
PIRIVU 
Karpu – Veppam – Karppu 
USES Nausea or pain associated with various 
ailments. Side effects, mostly associated with 
consuming powdered ginger, are gas, bloating, 
heartburn, and nausea. 
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ULUNTHU (VIGNA MUNGA): 
 
                       
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids   
ORDER Fabales    
FAMILY Fabaceae    
GENUS Vigna  
SPECIES Vigna mungo   
BOTANICALNAME Vigna mungo  
PARTS USED Seeds  
ACTION Stimulant, Stomachic,Carminative.  
 
SUVAI-THANMAI-
PIRIVU 
Inipu  – Veppam – Karppu 
USES Anti inflammatory properties, Nervous 
system disorders, Disorders of digestive 
system: 
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MAVILINGA PATTAI (CRATEAVA MANGNA): 
                
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids   
ORDER Brassicales  
FAMILY Capparaceae    
GENUS Crateva  
SPECIES C .mugna    
BOTANICALNAME Crateva magna   
PARTS USED Bark 
ACTION Rubefacient, laxative,lithontriptic.  
 
SUVAI-THANMAI-
PIRIVU 
Kaipu – Veppam – Karppu 
USES The decoction of bark is internally 
administered to cure diseases like 
renal calculi, dysuria, 
helminthiasis, inflammations and 
abscesses 
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KUNKILIYAM (VATRIA INDICA): 
                              
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Rosids   
ORDER Malvales  
FAMILY Dipterocaraceae     
GENUS Varteria  
SPECIES V  .indica    
BOTANICALNAME Vateria indica    
PARTS USED Resin  
ACTION Rubefacient, laxative,lithontriptic.  
 
SUVAI-THANMAI-
PIRIVU 
Kaipu – Veppam – Karppu 
USES Used in  treatment of gout, parkinson’s 
disease, neck stiffness, locked jaw, paralysis, 
thigh cramps, etc 
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SITHIRAMULAM (PLUMBAGO INDICA): 
                    
 
KINGDOM Plantae 
DIVISION Angiosperms 
CLASS Eudicots  
SUB CLASS Core eudicots  
ORDER Caryophyllales  
FAMILY Plumbaginacese    
GENUS Plimbago  
SPECIES P , indica    
BOTANICALNAME Plumbago indica 
PARTS USED Root  
ACTION Cathartic , Anthelmintic .  
 
SUVAI-THANMAI-
PIRIVU 
Siru Kaipu – Veppam – Karppu 
USES it is useful for the treatment of chronic 
respiratory problems, bronchitis and 
rheumatism. 
 
 
REVIEW OF LITERATURES |  
 
63 
VARMAM REVIEW
 
 
                                   
                                       
                       (strength),      (harden),      
(skill)                                            
        ஆ                     28. 
                       
1.             
2.            
3.             
4.            
5. ஆ           
 
      “                        
                                  
                               
                                      
                                
                                   
                                
                                          
                             -Varma Odivu Murivu Sara Soothiram-1200   
              ஆ                      
                   .              
                                           
                                         
                                   
                                         
                 . 
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Varmam are vital points in the body that act as energy transformers or batteries. 
They form centres for boosting the vital life-force Uyir Sakthi flow through the 
intricate nadi  system of the body. Nature, by its design, has protected these vital centres 
by placing them deep inside the body or by covering them with tissues inaccessible to 
normal attempts of breach. 
Varmam is a holistic therapy on its own and tackles the body, mind and spirit. A 
varmam expert understands the underlying links between the body, vital life-force and 
the mind. 
 
SITE OF VARMA: 
Varmam can be defined as the flow of life force in relationship with breathing.  
 
  
“                           
                                    
                            
                         46.”  
                                                                                                        - Varma Vidhi 
The vital points (varmams) are located in the junction of nerves, joints, bones, 
muscles, ligaments and internal organs. 
                        
                          47 
                                         -            
                             48’’ 
                               -                    
The points where life force resides and flows in the human body are known as 
varmam. It also means the points where breathing energy resides in the body. 
 
“                      49 ” 
                                    -                     
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OTHER NAME OF VARMA: 
 “                           
                        
                              
                            
                                     ’’  
                                  -                      
                                          
1. VANMAM 
2. KALAM 
3. ADAKKAM 
4. SUTSAMAM 
5. MARMAM 
6. EMAM 
7. EEDU 
8. AMIRTHA NILAI 
9. VAASITHANAM 
10. SARAM 
 
History of Varmam:            
      "                              
       ஆ                          ." 
                - Varma Odivu Murivu Sara Soothiram-1500, Song-833 
 Varmam kalai to the god Shiva who is said to have taught it to his wife Paarvathi 
later Paarvathi taught Varmam to their son Murugan. While disguised as an old man, 
Murugan passed the knowledge of varmam to the sage Agastya who then recorded it and 
disseminated the skill among his students. Siddha medicine is also attributed to Agastya. 
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     "                        
                                      
                               
                                  
                                    ." 
                                                                           -Kai Maathirai Thiravukoll 
 
 Varmam has grown under three independent schools of thoughts, mainly 
governed by three ancient siddhar’s namely Akasthianyar, Bohar and Rama Devar. The 
term Varmam appears in the Rigveda where Indran  hits Vritran in a Varmam with  his 
vajram. 
 All the poems in the suvadi are in tamil language. Sangam poets inaugurated 
many books at pothigai malai. Among them, varma patakotthu was the first and basic 
text for varamam.it was inagurated during the sangam periods. Tamil medicine had 
many divisions and  one among them is varamam. 
Aetiology of Varma: 
                              
                                   
                                
                                  
              ஆ             
                                 
                                
                                    
 
 Hit sustained by a thick and rough stick.  
 Stone thrown at a high speed from a sling.  
 Fall from a tree or height. 
 Fall while running. 
 By leaping.  
 By fainting          
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CLASSIFICATION OF VARMAM
24
: 
1. Based on varma kannadi 
                   Human body is divided into five  areas in which varmam.  
 
 
 
 
 
 
 
 
 
 
 
2.  Based on  Varma Odivu Murivu Soothiram 
The same 108 varmams are classified under different categories. One such 
classification is based on 12 nerves (or a meridian channel) in the nervous system. Each 
meridian channel consists of one Padu varmam and eight Thodu varmam. 
 
 
 
 
3. Based on the text Naramparai 
           written by Kumbamuni Siddha, there are 253 varmams: 
        
 
 
 
 
 
         
 
 
 
 
S.No  Area  Number of points  
1. From top of the head till neck  25 
2. From Neck till naval point 45 
3. From Naval point till  Anus 9 
4. Both hands  14 
5. Both leg 15 
TOTAL 108 
Varmam Type Number of Points 
Thodu Varmam 96 
Padu Varmam 12 
Total 108 
Classification Number of Points 
Padu Varman 18 
Thodu Varmam 96 
Pakka Varmam 8 
Narambu Elumbu Varmam 86 
Maru Varmam 45 
Total 253 
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4. Based on  the text Varma Soothiram: 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Based on yet another classification: 
                             There are 107 points: 
 
Classification Number of Points 
Vata Varmam  65 
Pitta Varmam  24 
Kapha Varmam  6 
Concealed Varmam 12 
Total 107 
 
Varmam treatment            
  Varmam therapy is a systematic study of vital points (varmam) on human body 
and also on animal bodies. 
 Varma therapy can be used for Low back ache, Spinal problems, Head ache  and 
Migraine, Arthritis, Frozen shoulder, Neuromuscular problems. It is a safe and effective 
system of healing and for rejuvenation. It provides a complete natural healing to 
rejuvenate the toxic imbalances. 
Classification Number of Points 
Vatha Varmam  64 
Pitta Varmam  24 
Kapha Varmam  06 
Ul varmam 06 
Thattu varmam 08 
Total 108 
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 In this present study, 60 cases of Thandagavatham were diagnosed clinically and 
40 cases of them were treated by Varmam treatment along with the trial drugs.  
The following Varmam points used for low backache: 
 Nanganapootu  Varmam 
 Naivari  adangal  
 Kaal mannai 
 Komberi Kaalam 
 Perunarambu adangal      
 Ullankaal vellai 
 NANGANA POOTTU  (NAAIRUPPU VARMAM) 
Synonyms – 
           Sorutheenda Varmam, Nattalu Varmam 
           Naairuppu Varmam- Varma Aani  
Putti Varmam      - Sathura Mani Soothiram 
Location:                   : 
i.Kumbamuni narambarai 108 
                              
                              
                          
ஆ                           
                                                                                         
  ii.Varma Aani -108 
     “                              
          .” 
  iii.Sathura Mani Soothiram 
      “                           
                              .” 
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Sacral groove or 3 fingers from the lumbosacral joint 
Site:   Sacroiliac articulation situated in the region of sacrum on both sides of  spinal 
column. 
Procedure: Give a pressure with palmar aspect of hands on both sides of sacroiliac 
joints. 
Indication: Lumbar spine related diseases.                                          
Uses:  Strengthen the lower limbs 
KOMBERI VARMAM 
Synonyms:  
Thumbikaala Varmam - Varma Noolavu Nool 
Komberi Varmam          - Varma Soothiram  
Location: 
 Komberi varmam is located  5 fingers below from the Kuthirai Mugha Varmam 
point (the middle of the both legs) in the anterior aspect of both legs. 
 “                (5      )         
                       .” 
  -Varma Noolalavu Nool  
  “................................           
                        
                        .” 
     “                     .” 
-Adi Varma Sootcham-500 
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 “                            
                               .” 
                                         -Varma Laada Soothiram-300 
 
Sign and symptoms: 
 Damage to Komberi Varmam leads to sweating, features mimicking tetanus and 
tiredness will set in. 
ULLANKAAL VELLAI VARMAM 
Synonyms  
  Adangal Varmam       - Varma Soothiram 1200   
 Kaal vellai Varmam   - Adivarma Sootcham 500  
 Allankaal Varmam    -  Varma Viralalavu Nool 
 Adikkuzhi  Varmam - Varma Vidhi 
 Vellai Varmam          - Varma Odivu Murivu Sara Soothiram 
 Location: In the centre of the plantar region. 
   “                       .” 
            - Varma Odivu Murivu Sara Soothiram -1200 
    “                       .”        
 - Varma Soothiram- 101 
    “                             
                   .....    
                                                                                                       -Varma Noolalavu Nool 
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  “                      .” 
- Varma Peerangi-100  
     “                     .”   
-Adi Varma Sootcham-500 
   
Symptoms:  
Fainting then death occurs. 
Retrieval techniques:  
 Massaging with medicated oil and taking head bath with oil cures eye diseases.  
Uses:  
 It cures giddiness, vomiting, faint, hysteria, convulsions and delirium. 
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4. MATERIALS AND METHODS 
  An open comparative clinical study on ―THANDAGA VATHAM (Lumbar 
Spondylosis)‖.with the evaluation of trial drug NAGA CHENDHURAM” (INT) 
“MOOLAYOGA  NIRKUNDI  THAILAM” (EXT)  AND  “VARMAM  THERAPY”. 
Study phase Phase II 
Methodology Open comparative clinical trial 
Study Duration 12 months 
Study Center 
Arignar Anna Government Hospital, Government Siddha Medical 
College, Chennai 
 
 INTERVENTIONS: 
―NAGA CHENDHURAM‖ (INT)  
―MOOLAYOGA  NIRKUNDI  THAILAM‖ (EXT) 
―VARMAM THERAPY‖ 
INTERNAL DRUG  : NAGA CHENDHURAM
 
REFERENCE  : ATHMA RAKSHAMIRTHA   ‖ page no.301 
EXTERNAL    : MOOLAYOGA NIRKUNDI THAILAM     
REFERENCE  : THERAYAR THAILAVARKA SURUKAM    
                                                       Page No.201                
 EXTERNAL THERAPY     : VARMAM THERAPY 
REFERENCE                       : SIRAPPU MARUTHUVAM 
                                                   VARMA 100 
                                                  KUMBAMUNI NARAMBARAI 108 
                                                  VARMA PADA  SUTHIRAM 300 
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SOURCE OF RAW DRUGS: 
The required raw drugs for the trial medicines will be purchased from a well reputed 
country raw drug shop and drugs will be authenticated. Then the raw drugs will be purified 
separately then the trial drugs will be prepared in Gunapadam Laboratory of Arignar Anna 
Government Hospital , Government Siddha Medical College . 
4.1 INTERNAL DRUG – NAGA CHENDURUM 
 
INGREDIENTS: 
          Nagam  (Zinc)                               - 35g    
          Manosilai(Red Orpiment)                                                                                             
          Soodham(Mercury)                           - each  35 g 
          Veeram (Hydrargyrum per chloride)                                                              
          Gandhagam (Sulphur)                       -  70 g 
           
          Ilupai nei (Oil of Madhuga longifolia) 
          Venkolinchi ver (Baptisia bracfeata )               -  Q.S  
          Potralai kayanthagarai (Eclipta prostrata )  
4.1 METHOD OF PURIFICATION
63
: 
Nagam (zinc): 
Nagam (zinc) is melted and poured in the oil of Madhuga longifolia (illupai nei). 
Repeat this for 10 times. Now zinc is get purified (fig 4.1.1) 
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METHOD OF PURIFICATION
22 
 
NAGAM PURIFICATION 
        
Fig 4.1.1                                                              
RASAM PURIFICATION 
       
Fig  4.1.2 
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GANDHAGAM  PURIFICATION: 
                 
Fig  4.1.3 
MANOSILAI PURIFICATION 
         
Fig  4.1.4 
VEERAM PURIFICATION  
         
Fig 4.1.5 
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Rasam (Mercury): 
35 grms of Mercury is triturated with brick powder and turmeric powder for one hour 
respectively and washed with water. Then the Mercury is boiled with the juice of Kuppai 
maeni (1.3 litters) until it is detoxified (fig  4.1.2) 
Gandhagam (Sulphur): 
       Sulphur is placed in an iron spoon. A small quantity of cow’s butter is added and the 
spoon is heated till the butter melts; this mixture is immersed in inclined position in cow’s 
milk. This procedure is repeated for 30 times to get purified Sulphur. Each time, fresh milk is 
to be used.fig (4.1.3) 
Manosilai (Red Orpiment):     
             Manosilai buried in limestone and poured by donkey urine to get purified. (Fig 4.1.4)   
Veeram (Mercury per Chloride): 
             Camphor is mixed with tender coconut water and placed in a mud pot. Veeram is tied 
in a cloth and soaked in the pot without touching the water and the pot is burnt out for half an 
hour Then Veeram is taken out and washed. (Fig 4.1.5) 
                
4.2 STANDARD OPERATING PROCEDURE OF NAGA  CHENDHURAM 
Nagam (zinc) is melted and poured in the oil of Madhuga Longifolia (Illupai Nei). 
Repeat this for 10 times. Now zinc is get purified , This purified Nagam (zinc) is placed inside 
the gugai and it is melted with the ulai. Here manosilai (Red orpiment) powder is added and 
stirred with the help of venkozhinji root (Baptisia bracfeata),then the whole content is turned 
into parpam .This prepared Parpam, Soodham (mercury), Veeram (Hydragram per chloride) 
are placed in stone mortar and grinded with milk for 4 samam(12 hours).Then sulphur is 
added and grinded well with Potralai Karippan (eclipta prostrata)  and bring into incineration 
process with 10 cow dung cakes. Repeat this incineration process for 6 more times. Finally it 
will turn into Chendurum.  
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DOSAGE           : 130 mg.Twice a day   for 48 days 
ADJUVANT      : HONEY 
INDICATION   : vathadiseases, kasam, valli kunmam erikunmam, kalleeralkatti, pun, 
soolai, krani, megham, edappattuerral noi manjal noi, kaichal,kulir, mandhara kasam. 
4.3 EXTERNAL MOOLAYOGA NIRKUNDI THAILAM     
        GROUP I   
1. Vennochi (Vitex negundo)  
2. Amanukku (Ricinus communis) 
3. Erukku (Calotropis gigantea) 
4. Amukkura (Withania sominifera) 
5. Pungu (Butea frodosa) 
6. Paruvagai (Mimosa sirissa)                                  - EACH  35 g 
7. Athondai (Capparis zelanica) 
8. Peramutty (Pavonia odorata) 
9. Punarmurugai (butea monosperma) 
10. Kuthiraivali (Echinochloa frumentacea) 
11. Ailamaram (Chukrasia tabulais)    
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GROUP II  
12. Thevatharu (cedrus deodara) 
13. Sukku (Zingiber officinale) 
14. Ulunthu (Vigna munga)   
15. Mavilinga pattai (Crateava mangna)                      -EACH 17g 
16. Kunkiliyam (Vatria indica)    
17. Sithiramulam (Plumbago indica)  
18. Water                                                                      - 5.2 ltrs 
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Fig : 4.3.1 
PREPARATION  
Take group I drugs and  put   into   the vessel.  Add water to the vessel and heated  to get 
decoction.  Then mix gingelly oil and goat milk to it. Finally the group II drugs grinded with 
above decoction is added and heated well until it turns into wax consistency. (Fig : 4.3.1) 
INDICATIONS: vatha disease 
DRUG STORAGE: 
 The trial drug is stored in clean air tight glass container and it is dispensed to the 
patients. 
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DISPENSING: 
 The chendhuram is given in the butter paper. External oil is given in pet bottles. 
 
4.4 STANDARDIZATION OF DRUG: 
 
4.4.1 Traditional way of testing Chendhuram 
 
1. Colour: 
Red in colour without any shiny appearance 
2. Taste and odour: 
                             Tasteless and odourless 
3. Luster 
                              Did not regain luster on heating again at same temperature 
4. Floating on water 
Sample floats on water. Did not immediately immersed in water 
5. Finger furrows test. 
                       Impinged in the papillary ridges when the sample rubbed in between  Index 
finger and thum 
 
4.4.2  PHYSICO CHEMICAL ANALYSIS 
 
Determination of Total Ash:  
 
Incinerate 2 g accurately weighed, of the drug in a tared silica dish at 450ºC  until free 
from carbon, cool and weigh. If a carbon free ash cannot be obtained in this way, exhaust the 
charred mass with hot water, collect the residue on an ash less filter paper, incinerate the 
residue and filter paper, add the filtrate, evaporate to dryness, and ignite at a temperature not 
exceeding 450ºC. Calculate the percentage of ash with reference to the air-dried drug. 
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Determination of Acid Water Soluble Ash:  
 
Boil the ash obtained in the above test for 5 minutes with 25 ml of distilled water 
repeatedly; collect the insoluble matter on an ash less filter paper, and ignite to constant 
weight. Calculate the percentage of water soluble ash with reference to the air dried drug. 
 
Determination of Acid Insoluble Ash:  
 
Boil the ash obtained in the above test for 5 minutes with 25 ml of dilute hydrochloric 
acid repeatedly; collect the insoluble matter on an ash less filter paper, wash with hot water 
and ignite to constant weight. Calculate the percentage of acid-insoluble ash with reference to 
the air dried drug. 
 
Determination of Loss on Drying: 
Place about 10 g of drug (without preliminary drying) after accurately weighing 
(accurately weighed to within 0.01 g) it in a tared evaporating dish. After placing the above 
said amount of the drug in the tared evaporating dish dry at 105º for 5 hours, and weigh. 
Continue the drying and weighing at one hour interval until difference between two 
successive weighings corresponds to not more than 0.25 per cent. Constant weight is reached 
when two consecutive weighings after drying for 30 minutes and cooling for 30 minutes in a 
desiccator, show not more than 0.01 g difference. 
 
Determination of pH: 
 
Take 10 g of sample, add 100 ml of distilled water, stir well and filter.  Use the filtrate 
for the experiment. Switch on the instrument. Give 30 minutes time for warming pH meter.  
Introduce the pH 4 solution first and adjust the pH meter by using the knob to 4.00 for room 
temperature 20°C, 4.01 for room temperature 25°C, 4.02 for room temperature 30°C.  
Introduce the pH 7 solution and adjust the pH meter to 7 by using the knob.  Introduce the pH 
9.2 solution and check the pH reading without adjusting the knob.  Then introduce the sample 
solution and note the reading. Repeat the test four times and take the average reading as resul 
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4.4.3 HEAVY METAL ANALYSIS 
Heavy metal Procedure Observation  
Mercury 
1.Add 5ml of hydrochloric acid  
to little substance, precipitate 
appears 
2.Then  boil the precipitate 
with water. It does not 
dissolves add sodium 
hydroxide solution .heat it and 
filter 
No Black precipitaion 
appears 
Lead 
1.add 2ml of potassium 
chormate to salt solution. 
No yellow precipitate 
appears 
Arsenic 
To 10 drops of solution. Add 
6ml NH3  until neutral.make 
the solution acidic b adding 
one or more drops of 6 M 
HCL. Add 1 ml of 
thioacetamide and stir well. 
Heat the test tube in the boiling 
water bath for 5 minutes 
No  red orange precipitate 
Or 
Yellow or brown 
precipitates appears 
Cadmiam 
add 2ml of solution, add 1 ml 
NaOH, add  1ml of distal water 
and add  1 ml of Hcl 
No Yellow  precipitates 
appears
 
Chromium 
To 10 drops of solution, add 
1ml of 3% H2O2 then add 6M 
NaOH dropwise untill the 
solution is basic. Heat in a 
boiling water bathh for a few 
minutes 
No  yellow solution of 
CrO4
2 
form 
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4.5 TOXICOLOGICAL STUDY  
 
4.5.1 ACUTE ORAL TOXICITY STUDY OF NAGA CHENDHURAM 
(OECD GUIDELINE – 423)     
 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals of a 
single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on average 2-4 
steps may be necessary to allow judgement on the acute toxicity of the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank substances in 
a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification purposes and 
hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise LD50, but 
does allow for the determination of defined exposure ranges where lethality is 
expected since death of a proportion of the animals is still the major endpoint of this 
test.  
 The method allows for the determination of an LD50 value only when at least two 
doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of a minimum 
number of animals per step, sufficient information is obtained on the acute toxicity of the test 
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substance to enable its classification. The substance is administered orally to a group of 
experimental animals at one of the defined doses. The substance is tested using a stepwise 
procedure, each step using three animals of a single sex. Absence or presence of compound-
related mortality of the animals dosed at one step will determine the next step, i.e. 
− no further testing is needed 
 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose level. The 
method will enable a judgment with respect to classifying the test substance to one of a series 
of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wister rat, although other rodent species may be 
used. Healthy young adult animals are commonly used laboratory strains should be employed. 
Females should be nulliparous and non-pregnant. Each animal, at the commencement of its 
dosing, should be between 6 to 8 weeks old and the weight (150-250gm) should fall in an 
interval within±20 % of the mean weight of any previously dosed animals.  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  Although the 
relative humidity should be at least 30% and preferably not exceed 70% other than during 
room cleaning the aim should be 50-60%. Lighting should be artificial, the sequence being 12 
hours light, 12 hours dark. For feeding, conventional laboratory diets may be used with an 
unlimited supply of drinking water. Animals may be group-caged by dose, but the number of 
animals per cage must not interfere with clear observations of each animal. 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and kept in 
their cages for at least 7 days prior to dosing to allow for acclimatization to the laboratory 
conditions 
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Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS,Madhavaram, Chennai. All the animals were kept under standard environmental 
condition (22±3°C).  The animals had free access to water and standard pellet diet (Sai meera 
foods, Bangalore). 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and kept in 
their cages for at least 7 days prior to dosing to allow for acclimatization to the laboratory 
conditions 
 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to administration of the, 
Naga Chendhuram. 
The principles of laboratory animal care were followed and the Institutional Animal Ethical 
Committee approved the use of the animals and the study design 
 
IAEC approved  Number: IAEC/XLVIII/32/CLBMCP/2016 
 
Test Substance  : NAGA CHENDHURAM 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual    
                               marking by using Picric acid. 
Numberofanimals                  : 3 Female/group,  
Routeofadministration          :   Oral  
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Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd, Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
                                    provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
 
Administration of Doses:  
 Naga Chendhuram was suspended in water and administered to the groups of wistar 
albino rats in a single oral dose by gavage using a feeding needle. The control group received 
an equal volume of the vehicle. Animals were fasted 12 hours prior to dosing. Following the 
period of fasting, the animals were weighed and then the test substance was administered. 
Three Female animals are used for each group. The dose level of 3mg/kg body weight was 
administered. After the substance has been administered, food was withheld for a further 3-4 
hours. The principle of laboratory animal care was followed. Observations were made and 
recorded systematically and continuously as per the guideline after substance administration. 
The visual observations included skin changes, mobility, aggressively, sensitivity to sound 
and pain, as well as respiratory movements. Finally, the number of survivors was noted after 
24 hrs and these animals were then monitored for a further 14 days and observations made 
daily. The toxicological effect was assessed on the basis of mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 minutes, 
periodically during the first 24 hours, with special attention given during the first 4 hours, and 
daily thereafter, for a total of 14 days, except where they need to be removed from the study 
and humanely killed for animal welfare reasons or are found dead. It should be determined by 
the toxic reactions, time of onset and length of recovery period, and may thus be extended 
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when considered necessary. The times at which signs of toxicity appear and disappear are 
important, especially if there is a tendency for toxic signs to be delayed. All observations are 
systematically recorded with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, and also 
respiratory, circulatory, autonomic and central nervous systems, and somatomotor activity and 
behavior pattern. Attention was directed to observations of tremors, convulsions, salivation, 
diarrhoea, lethargy, sleep and coma. The principles and criteria summarized in the Humane 
Endpoints Guidance Document taken into consideration. Animals found in a moribund 
condition and animals showing severe pain or enduring signs of severe distress was humanly 
killed. When animals are killed for human reasons or found dead, the time of death was 
recorded. 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours which  
includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, convulsion, 
excitation, head twitches, lacrimation, loss of corneal reflex, loss of traction, piloerection  
reactivity of touch, salivation, scratching, sedation, chewing,  head movements, sniffing, 
straub, tremor and writhes, diarrhea, leathery, sleep and coma.  
Body Weight:  
Individual weight of animals was determined before the test substance was administered and 
weights will be recorded at day 1, 7, and 14 of the study. Weight changes were calculated and 
recorded. At the end of the test, surviving animals were weighed and humanly killed. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose groups.  
Mortality: 
Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test group the 
number of animals used, the number of animals displaying signs of toxicity, the number of 
animals found dead during the test ,description of toxic symptoms,, weight changes, food and 
water intake. 
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4.5.2   SUB ACUTE TOXICITY 
REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF 
NAGA CHENDHURAM 
Test Substance  : Naga Chendhuram 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
 marking by using    Picric acid 
Diet    : Pellet feed supplied by Sai meera foods PvtLtd,     
                                  Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
                      provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
Table 5  
 NACM -NAGA CHENDHURAM 
Groups No of Rats 
Group I  Vehicle control (Water) 12(6male,6 female) 
Group II NACM- low dose X (3mg) 12 (6male,6 female) 
Group III NACM- Mid dose  5X (15mg) 12 (6male,6female) 
Group IV NACM- High dose 10X( 30 mg) 12(6male,6female) 
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Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. Each group 
consist of 12 animals (Male -6, and Female-6). First group treated as a control and other three 
group were treated with test drug (low, mid, high) for  28 days. Animals were allowed 
acclimatization period of 7 days to laboratory conditions prior to the initiation of treatment. 
Each animal was marked with picric acid. The females were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are low dose 
(X), mid dose dose (5X), high dose (10X). X is calculated by multiplying the therapeutic dose 
(130 mg) and the body surface area of the rat (0.018). i.e X dose is (2.34mg—rounded to 
3mg),  5X dose is 15mg/animal,10X dose is 30mg/animal. 
 
Preparation and Administration of Dose: 
Naga Chendhuram suspended in prescribed medium , It was administered to animals at the 
dose levels of X, 5X, 10X. The test substance suspensions were freshly prepared every two 
days once for 28 days. The control animals were administered vehicle only. The drug was 
administered orally by using oral gavage once daily for 28 consecutive days. 
Observations: 
Experimental animals were kept under observation throughout the course of study for 
the following: 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and duration of 
these symptoms, if any, were recorded. 
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Mortality: 
All animals were observed twice daily for mortality during entire course of      study. 
Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy of all animals 
was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted over-night. 
Blood samples were collected from orbital sinus using sodium heparin (200IU/ml) for Bio 
chemistry and potassium EDTA (1.5 mg/ml) for Hematology as anticoagulant. Blood samples 
were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations: 
Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group than the 
low, then the mid dose group will also be examined. Organs will be collected from all animals 
and preserved in 10% buffered neutral formalin for 24 h and washed in running water for 24 
h.  The organ sliced 5 or 6µm sections and were dehydrated in an auto technicon and then 
cleared in benzene to remove absolute alcohol. Embedding was done by passing the cleared 
samples through three cups containing molten paraffin at 50°C and then in a cubical block of 
paraffin made by the ―L‖ moulds. It was followed by microtome and the slides were stained 
withHaematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, hematology and blood 
chemistry were subjected to One-way ANOVA followed by dunnet-t test using a computer 
software programme – Graph pad  version 7.All data were summarized in tabular form, 
(Table-6 to 12) 
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4.6 PHARMACOLOGICAL STUDY 
4.6.1 ANALGESIC ACTIVITY 
Eddy’s Hot plate method in rats 
The  hot  plate  assay  method  was  employed  for  the  purpose  of  preferential  assessment  
of  possible analgesic effects  of Naga Chendhuram (NCM) The analgesic drug, Pentazocine, 
was used for positive control group. In this experiment, four groups (n=6) of wister rats (200–
250 g) were placed on a hot plate maintained at room temperature for 15 min. Food was 
withdrawn on the preceding night of the experiment. Group-1 normal control (0.5% CMC 
p.o.), and group-2 Pentazocine (30mg/kg, i.p.), whereas groups-3 and 4 animals received 
Naga Chendhuram (NCM)(15and 30 mg/kg, p. o respectively).  Each animal was then 
individually placed gently on Eddy’s hot plate at 55oC. Latency to exhibit nociceptive 
responses such as licking paws or jumping off the hot plate, were determined 15, 30, 45and 
60min after administration of the test drug or vehicle. 
4.6.2 Anti-inflammatory studies using Naga Chendhuram (NCM) 
For the experiment, the animals were divided into 5 groups with 6 animals in each group. 
Group-I (control) received 3% gum acacia 10 ml/kg p.o. 
Group-II (Carageenan) received 0.1ml of 1% w/v suspension of carrageenan S.C 
Group-III (standard) received Indomethacin 40 mg/kg p.o. 
Group-1V(Test-1) received NCM15mg/kg p.o. 
Group-V(Test-2) received NCM 30mg/kg p.o. 
All the drugs were administered orally and the volume of medicaments kept constant at 10 
ml/kg body weight of the animals it was administered orally to rats 1 hr before subcutaneous 
injection of carrageenan. After 1 hr 0.1ml of 1% w/v suspension of carrageenan was injected 
into sub-plantar region of the left hind paw to all the groups. The paw volume was measured 
at 1, 2, 3, 4, and 5 hr using Plethysmometer (Model 7150 UGO Basile, Italy) Edema was 
expressed as the mean increase in paw volume relative to control animals. 
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 4.7   CLINICAL  STUDY  
VARMA   PULLIGAL 
 Nangana Pootu –In between the lumbar vertebrae and sacrum 
 Naivari Adangal-dimple present 5 fingers lateral to Nangana Pootu  
 Kaal Mannai- At the end of the calf muscle 
 Komberi Kalam-  Fingers above medial malleolus  
 Perunarambu Adangal- At the center of popliteal fossa  
 Ullangal Vellai- Present in plantar region 
STUDY DESIGN 
Study type  : An Open Comparative Clinical trial 
Study Place  : Room no. 4, PG Sirappu Maruthuvam OPD,  
OPD of Arignar Anna Hospital, GSMC 
Chennai-106 
Study Period  : 12 months after completion of Preclinical studies. 
Sample size  : 60 patients OPD 
20   Cases -Under  External drug and vermam therapy  
20   Cases -Under   both Internal and external drugs 
20   Cases -Under internal, external drug and varmam therapy 
SUBJECT SELECTION  
 As and when patients reporting at Room no. 04, PG Sirappu Maruthuvam OPD, Aligner 
Anna Govt. Hospital, GSMC with the symptoms of inclusion criteria will be subjected to 
screening test and documented using screening proforma.  
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INCLUSION CRITERIA 
 Age : 35-60 
 Sex : Both male and female 
 Patients having any one of the symptoms of lower back pain radiates to the lower 
extremities anteriorly, tenderness, numbness. 
 Limitation of lower back movements. 
 Patient willing to sign consent form.  
EXCLUSION CRITERIA 
History of 
 Traumatic condition 
 Inter vertebral disc prolapse 
 Ankylosing spondylosis 
 Spondylolisthesis 
 Neoplasm 
 Congenital anamolies 
 Gibbus  deformity 
 Sacralization 
 Cardiac diseases 
 Pregnant women and lactating mother 
 Patients with any other serious systemic illness 
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WITH DRAWL CRITERIA: 
 Intolerance to the drug and development of adverse reaction during drug trial. 
 Poor patient compliance and defaulters. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness 
 SRD REPORTING.  
     ADR REPORTING 
 If ADR is reported patients will be referred to SCRI(Peripheral Pharmacovigilance 
centre) 
 
MODERN INVESTIGATION: 
BLOOD INVESTIGATION 
            Total Blood count,  
Blood sugar(F), (PP) , 
Lipid profile,   
Renal function test,  
Liver function test 
RADIOLOGICAL INVESTIGATIONS 
           X-ray: Lumbar spine AP view ,  Lateral view 
CLINICAL ASSESSMENT: 
Pain Management – Access by visual pain analogue scale 
Acute and Chronic Stage 
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Improvement in range of Movements 
Forward Bending 
Backward Bending 
Pain during  Walking 
Slow Walking 
Fast Walking 
Improvement in Confortability  
In Prolonged Sitting Position 
In Prolonged Standing Position 
 
ASSESSMENT TOOL- VISUAL   ANALOG   SCALE 
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METHODOLOGY OF TREATMENT  
STUDY ENROLMENT 
Patient reporting at the OPD with any one of the symptoms of low back pain , 
tenderness, tingling sensation, transient numbness, limitation of lower back movements, 
above symptoms radiates to the lower extremities anteroirly,  are chosen for enrolment based 
on the inclusion criteria. The patients who are enrolled are informed about the study trial drug, 
possible out comes and the objectives of the study in the language and terms understandable 
to them and the informed consent would be obtained in writing from them in the consent 
form.  
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT FORM 
 
ADVERSE REACTION 
ADVISED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
PHARMOCOVIGILANCE 
FURTHER MANAGEMENT 
OF ADVERSE DRUG 
REACTION 
Both Internal 
and external 
drugs 
 
Internal 
drug and 
varmam 
 
Internal, 
external drugs 
and varmam 
Internal 
alone 
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Conduct of the study 
              The trial drug “NAGA   CHENDHURUM” (internal) will be given in the opd 
department of   Sirappu Maruthuvam for 60 patients. The trial drug “NAGA   
CHENDHURUM”  will be given along with “VARMAM  THERAPY” with the oil “: 
MULAYOGA NIRKUNDI THAILAM    ”(external) in opd for another 60 patients, gsmc, 
Chennai the patients will be asked to have a regular follow up in the op department once in 7 
days. In each and every visit the clinical assessment will be recorded in the prescribed 
proforma. The laboratory investigation will be done before and after treatment and recorded in 
the prescribed format. At the end of the trial the patients are advised to come to op if the same 
symptom arises after 2 months of trial.  
 
ASSESSMENT OF RESULTS: 
 
CRITERION MEASURES Physical 
level 
1. Visual Analog Scale- Pain 
 
2. Range of movements.. 
 
 
 
RELIABILITY OF DATA 
 
 The reliability of data was ensured by using standard instruments and by establishing 
tester competency reliability of the test.   In this the data was based on getting  details  from  
the  subjects  through     pain  scale  questionnaire.  Hence  no instruments were needed and used 
 
 
RELIABILITY OF INSTRUMENTS 
 
 The  pain scale questionnaire alone used to collect the needed data to measure the pain 
related variable. 
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TESTER’S RELIABILITY 
 
 Reliability was established as the pain scale questionnaire was a standard one. 
 
ORIENTATION OF THE SUBJECTS 
 
 Before collection of the data, the subjects were oriented according to the purpose of 
the study. The subjects were properly guided as how to mark the pain score in the questionnaire. 
The  investigator  had  explained  the  tests  to  the  subjects  and  about  the procedure adopted for 
assessing the pain management. 
 
i. Visual Analog Test- Pain.  (0-10) 
 
Purpose           : To measure the intensity of pain 
 
Equipments     : Questionnaire 
 
Recording       : Recorded in relaxed sitting position 
 
Scoring            : Zero to ten 
 
Statistical Technique: 
 
 Data collected were entered in Excel Spread sheet and analyzed using STATA 
statistical  software  package  release  11.  Universal  pain  scale  was  used  to classify  the 
degree  of pain  in each  group  (note  2). Improvement  before  and after treatment were 
grouped as shown in note 3. We used paired t test to compare mean difference between pain 
scores before and after treatment in each arm; the one-way ANOVA test for comparison of 
means across multilevel variables. Simple calculations like Percentages, Proportions and 
Mean values were derived. A type I error of 0.05 was considered in all analyses. 
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Note 1: PAIN ASSESMENT SCALE 
UNIVERSAL PAIN ASSESMENT 
0      ---------- No pain 
 
1-3    ---------- Mild pain 
 
4-6    ---------- Moderate pain 
 
7-10 ---------- Severe pain 
 
DATA COLLECTION FORMS 
                Required information will be collected from each patient by using  following forms. 
FORM l          : Screening and Selection Proforma  
FORM lI    : History taking Proforma  
FORM llI     : Clinical Assessment Proforma 
FORM lV : Laboratory Investigation Proforma  
FORM V       : Informed Consent Form 
FORM VI    : Withdrawal Form 
FORM VII     : Patient Information Sheet 
FORM VIII    : Dietary advice Form  
FORM IX            : Adverse reaction Form 
DATA ANALYSIS:  
After enrolling the patients in the study a separate file for each patient will be maintained 
and all forms will be kept in the file. Whenever the patient visits OPD during the study period 
necessary entries will be made in the assessment forms. The data entries and adverse events if 
any will be monitored by the Head of the Department. 
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OUTCOME OF TREATMENT 
PRIMARY OUTCOME: 
 Pain reduction is evidenced by pain assessment scale   (visual analogue scale).  
 Reduction of stiffness and pain present in the lumbar region. 
 Improvement in the range of movements of lumbar region. 
 Improvement in ability to sit, stand and walk for a long time without pain. 
SECONDARY OUTCOME: 
        Secondary outcome is assessed by comparing the safety parameters before and after 
treatment 
 
ETHICAL ISSUES: 
 Informed consent will be obtained from the patients after explaining about the clinical 
trial in an understandable language. 
 After the consent of the patient (through consent form) they will be enrolled in the study. 
 Treatment will be provided free of cost 
 No other medicines will be used except the trial drug 
 The data collected from the patient will be kept confidentially. The patient will be 
informed about the diagnosis, treatment and follow up. 
 The patients who are excluded (as per the exclusion criteria) are given proper treatment 
with full care at OPD. 
 In conditions of treatment failure, adverse reactions patients will be given alternative 
treatment at the OPD with full care through the end.  
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5. RESULTS AND OBSERVATION 
 
5.1 ORGANOLEPTIC CHARACTER 
 
S.NO  CHARACTERS  RESULTS  
1     COLOUR  Red  
2     TASTE  Tasteless  
3     ODOUR  Odourless 
4     APPERENCE  Fine powder  
5     SOLUBILITY  Soluble in water and alcohol  
 
 
5.2 TRADITIONALTESTING METHOD FOR CHENDHURAM 
S.  
NO  
            TESTS  INFERENCE  
1  Floating of water       +  
2  Finger furrows test       +  
3  Lusterless       +  
4  Tasteless       +  
5  Colour   Red  
 
Inference: 
 Regarding TRADITIONALTESTING METHOD  Floating of water, Finger furrows 
test, Lusterless, Tasteless were present, red Colour were observed. 
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5.3 PHYSICO-EMICAL ANALYSIS RESULTS       
                           
S.NO  PARAMETERS  MEAN RESULTS  
1  Loss on drying at 105
0
C  Nil  
2  Total ash  92.38%  
3  Water soluble ash  33.51%  
4  Acid soluble ash  46%  
5  P
H
 6.77  
 
 
5.4 QUALITATIVE ANALYSIS OF HEAVY  METAL 
  
 
 
 
 
 
 
ND – NON DEDECTABLE 
 
 
 
 
S.NO   HEAVY METALS         RESULTS  
 1    Lead            ND  
 2    Mercury            ND  
 3    Arsenic            ND  
 4    Cadmium            ND  
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5. 5 TOXICITY STUDY:   
  
PREPARATION OF ANIMALS:   
 
  The animals are randomly selected, marked to permit individual identification, and  kept in their 
cages for at least 7 days prior to dosing to allow for acclimatization to the laboratory conditions.  
   
SL 
Group 
Control 
Observation 
Group 
Test Group 
Observation 
1 Body weight Normal Body weight 
Normally increased 
 
2 
Assessments of 
posture 
Normal 
Assessments of 
posture 
Normal 
3 
Signs of 
Convulsion 
Limb paralysis 
Normal 
Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal Body tone Normal 
5 Lacrimation Normal Lacrimation Absence 
6 Salivation Normal Salivation Absence 
7 
Change in skin 
color 
No significant color 
change 
Change in skin 
color 
No significant color 
change 
8 Piloerection Normal Piloerection Normal 
9 Defecation Normal 
 
Defecation Normal 
 
10 
Sensitivity 
response 
Normal Sensitivity response Normal 
11 Locomotion Normal Locomotion Normal 
12 Muscle gripness Normal Muscle gripness Normal 
13 Rearing Mild Rearing Mild 
14 Urination Normal Urination Normal 
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Table 2 (Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
3mg 
 
+ - - + - + - - - - - - - - - - - - - - 
  
(+  Present, -  Absent) 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. 
Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. 
Exophthalmos 17. Diarrhea 18. Writhing 19. Respiration 20. Mortality. 
 
Table 3 ( Body weight Observation) 
 
 
 
 
 
 
 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 210.6±31.474  211.2 ± 14.162 220.2 ± 24.22 
HIGH DOSE 220.5± 27.75 221.4 ± 3.22 224.1 ± 12.72 
P value (p)* NS NS NS 
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Table 3: Water intake (ml/day) of Wistar albino rats group exposed to (Naga  
Chendhuram): 
DOSE 
 
DAYS 
1 6 14 
CONTROL 54 ± 2.22 53±7.42 58.4±2.54 
HIGH DOSE 62.2±1.21 62.8±4.46 64.6±2.22 
P value (p)* NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
Table 4: Food  intake (gm/day) of Wistar albino rats group exposed to  
Naga Chendhuram 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 45.24±6.32 45.2±6.32 45.4±4.16 
High DOSE 42.2±1.44 44.8±2.32 46.1±4.14 
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SUB ACUTE TOXICITY REPORTS 
REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF 
NAGA CHENDHURAM 
 
NACM -NAGA CHENDHURAM 
 
Repeated Dose 28- day oral toxic study of Naga Chendhuram 
Table 6: Body weight of wistar albino rats group exposed to  NagaChendhuram 
 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
Groups No of Rats 
Group II NACM- low dose X (3mg) 12 (6male,6 female) 
Group III NACM- Mid dose  5X (15mg) 12 (6male,6female) 
Group IV NACM- High dose 10X( 30 mg) 12(6male,6female) 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 260.4±12.42  261.4 ± 20.14 261.7 ± 19.60 262.6 ± 19.16 262.4 ± 12.12 
LOW DOSE 240.2 ± 10.12 240.7 ± 38.24 241.4± 42.14 243 ± 52.16 242.42± 12.54 
MID DOSE 196.4± 08.74 196.3 ± 12.14 196.2 ± 88.14 198.1 ± 13.66 199.4 ± 22.10 
HIGH DOSE 207.6± 16.84 207.8 ± 12.42 208.4 ± 22.26 208 ± 24.18 209 ± 56.41 
P value (p)* NS NS NS NS NS 
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Table 7: Water intake (ml/day) of  Wistar albino rats group exposed to Naga Chendhuram 
 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 55.9 ± 9.72 56±8.22 57.2±2.20 59±2.16 59.4±2.16 
LOW DOSE 58.2±1.21 58.8±3.22 58.9±1.62 60.2±1.28 60.8±1.23 
MID DOSE 62.2±2.12 62.3±1.12 63.1±2.422 63.4±1.14 68.4±1.32 
HIGH DOSE 64.1±1.21 64.2±1.24 64.4±1.14 64.6±1.42 66.8±2.52 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way ANOVA 
followed by Dunnett’s test) 
 
 
Table 8: Food intake (gm/day) of Wistar albino rats group exposed to Naga 
Chendhuram 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 27±5.14 28.5±2.12 29.5±2.17 28.5±1.18 27±2.16 
LOW DOSE 29.7±1.18 29.3±1.41 30.1±1.16 30.4±1.21 31.6±1.42 
MID DOSE 37.2±2.44 37.2±3.60 37.2±4.25 38.2±2.18 38.2±1.44 
HIGH DOSE 29.1±1.14 29.1±1.24 29.6±2.16 29.2±1.20 29.6±3.32 
P value (p)* NS NS NS NS NS 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test 
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Table 9: Haematological parameters of Wistar albino rats group exposed to Naga 
Chendhuram 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 14.8±0.58 14.80±0.64 15.4±0.66 15.18±0.44 N.S 
Total WBC (×10
3   
l) 
7.91±0.52 7.25±0.16 7.48±0.17 7.20±1.32 N.S 
Neutrophils (%) 30.25±0.04 31.22±0.12 32.10±1.32 33.06±1.20 N.S 
lymphocyte (%) 61.14±1.42 60.12±2.10 60.10±2.22 60.40±2.26 N.S 
Monocyte (%) 1.86±0.07 1.85±0.09 1.66±0.03 1.81±0.06 N.S 
Eosinophil (%) 0.62±0.04 0.65±0.02 0.66±0.01 0.63±0.06 N.S 
Platelets cells10
3
/µl 786.14±4.42 788.41±4.16 783.13±7.0 787.16±6.74 N.S 
Total RBC 10
6
/µl 6.88±0.12 6.86±0.46 6.62±0.44 6.15±0.22 N.S 
PCV% 47.56±0.6 47.46±1.13 48±1.28 47.80±2.24 N.S 
MCHC g/dL 34.4±1.32 34.6±1.28 34.28±1.20 34.33±1.12 N.S 
MCV fL(µm
3
) 52.07±3.24 52.20±1.21 53.10±1.34 54.24±1.42 N.S 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
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Table 10 : Biochemical Parameters of Wistar albino rats group exposed to Naga 
Chendhuram 
 
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
GLUCOSE (R) (mg/dl) 80.24±10.6 80.16±6.14 81.22±14.10 81.62±10.2 N.S 
T.CHOLOSTEROL(mg/dl) 128.16±1.42 129.25±1.22 126.82±1.28 126.22±1.83 N.S 
TRIGLY(mg/dl) 58.36±1.42 58.32±1.28 59.56±1.32 59.66±1.23* N.S 
LDL 81.6±2.53 83.14±2.34 83±2.42     83.44±14.15 NS 
VLDL 16.2±2.34 16.42±4.44 16.44±8.24 16.34±24.26 NS 
HDL 30.16±6.18 30.26±2.25 32.28±4.26 34.48±20.12 NS 
Ratio 1(T.CHO/HDL) 4.12±2.16 4.16±2.14 4.14±2.24 4.26±2.20 NS 
Ratio 2(LDL/HDL) 
 
2.70±1.18 2.74±2.12 2.76±3.10 2.76±18.02 NS 
Albumin (g/dL) 
4.3±0.26 4.63±0.42 4.64±12.42 
4.72±15.68 
NS 
  
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
Table 11: Renal function test of Wistar albino rats group exposed to Naga 
Chendhuram 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 23.32±0.99 24.28±0.46 24.16±1.28 24.68±1.22 N.S 
CREATININE(mg/dl) 0.62±0.08 0.61±0.04 0.62±0.06 0.64±0.08 N.S 
BUN(mg/dL) 17.1±0.13 17.10±0.80 17±0.42 17.47±1.12 NS 
URIC ACID(mg/dl) 6.22±0.34 6.11±0.22 6.72±0.24* 6.42±0.26 N.S 
 
 NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
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Table 12: Liver Function Test of Wistar albino rats group exposed to Naga 
Chendhuram 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)*  
T BILIRUBIN(mg/dl). 0.06±0.06 0.05±0.08 0.6±0.06 0.6±0.04 N.S 
SGOT/AST(U/L) 119.15±1.32 119.34±0.52 120.01±1.22 119.75±1.03 N.S 
SGPT/ALT(U/L) 70.13±2.18 70.21±1.44 70.14±1.28 71.12±0.48 N.S 
ALP(U/L) 133.52±4.26 134±12.14 135.12±14.04* 134.23±12.25* N.S 
T.PROTEIN(g/dL) 7.72±0.36 7.78±0.32 7.76±0.24 7.53±0.48 N.S 
 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
HISTOPATHOLOGY OF KIDNEY: 
 
                           CONTROL                                                         HIGH DOSE 
                                                                                    
Report  
Section studied shows normal glomerulus and renal tubules. 
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HISTOPATHOLOGY OF SPLEEN 
 
 
                       CONTROL                                                        HIGH DOSE 
                   
Report  
 
Section studied shows plenty of intra parenchymal hemosiderin laden macrophages. 
 
 
 
 
HISTOPATHOLOGY OF LIVER 
 
                      CONTROL                                                        HIGH DOSE 
 
                  
Report   
 
  
Section studied shows normal lobular pattern 
 
 
 
 
R e s u l t s  a n d  O b s e r v a t i o n  |  
 
114 
 
ANTI-INFLAMMATORY STUDIESUSING NAGACHENDHURAM      
(NCM) 
 
 
Group Initial paw 
volume 
5 hr in mm Difference in paw 
volume 
Percentage protection  
I 1.20 ± 0.14 1.20±0.14 0.00 100 
II 1.21± 0.17 2.62 ± 0.17 1.41 15.59 
III 1.01± 0.06 1.15 ± 0.16 
 
0.24 86.67 
IV 1.17 ± 0.13 1.28 ± 0.22 0.05 20.65 
V 1.02 ±0.20 1.37 ± 0.28 0.25 60.16 
 
Percentage protection is calculated by the formulae:  (T2---T1/ T2)x 100 
T 1----normal control 
T2----drug treated test 
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ANALGESIC ACTIVITY: 
 
Groups Dose 
Mg/kg 
Reaction time  
15 mins 30mins 45 mins 60 mins  
Control 10 2.2±.0.2 2.1±0.4 2.4±0.6 1.9±0.2 
Pentazocine 30 4.5±0.2 7.2±0.4 7.9±0.6 9.6±0.6 
Naga Chendhuram 
(NCM) 
15 2.9±0.6 3.8±0.6 4.8±0.6 5.8±0.6 
Naga Chendhuram 
(NCM) 
30 4.3±0.8 4.9±0.4 6.7±0.2 7.6±0.8 
N=6 ;Statistical analysis one way ANOVA followed by Dunnett t-test. 
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                                              1. AGE DISTRIBUTION 
S.No AGE IN YEARS NUMBER OF 
CASES 
PERCENTAGE (%) 
1                 35-40yrs 16 27% 
2                 41-50yrs 26 43% 
3                  51-60 yrs  18 30% 
 
                      
 
INFERENCE 
Majority of the case that is 27% were in the3
rd
 decade, 43% were in the 4
th
 decade, 30% 
were in the 5
th
 decade. 
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2.OCCUPATION 
S.No OCCUPATION NUMBER OF 
CASES 
PERCENTAGE (%) 
1 Engineer 5 9% 
2 House Wife 24 40% 
3 Business 8 13% 
4 Tailor 5 8% 
5 Cooli 3 5% 
6 Teacher 6 10% 
7                 Computer base job 9 15% 
 
 
                      
  
 
INFERENCE 
 0ut of 60 patients (100%), 40 were house wife,9% were Engineer, 13% were 
Business, 8% were Tailor, 5% were cooli,10% were teacher, 15% were in computer base 
job. 
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3.SOCIO – ECONOMIC STATUS 
S.No SOCIO – ECONOMIC 
STATUS 
NUMBER OF 
CASES 
PERCENTAGE 
(%) 
1 Low Income  
 
25 42% 
2 Moderate Income  
 
25 42% 
3              Higher income 10 16% 
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4.DIETARY HABITS 
 
S.No DIET NUMBER OF 
CASES 
PERCENTAGE 
(%) 
1 Vegetarian 14 30% 
2 Mixed diet 46 70% 
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5. SEASONAL OCCURENCE 
S.No KAALAM (Season) NUMBER OF CASES PERCENTAGE (%) 
1 
Kaarkaalam 
( Mid Aug – Mid Oct) 
3 15% 
2 
koothirKaalam 
(Mid Oct – Mid Dec) 
4 20% 
3 
Munpanikaalam 
(Mid Dec – Mid Feb) 
10 50% 
4 
Pinpanikaalam 
(Mid Feb – Mid Apr) 
3 15% 
5 
Elavenirkaalam 
(Mid Apr – Mid Jun) 
0 0% 
6 
Muthuvenirkaalam 
(Mid Jun – Mid Aug) 
0 0% 
 
 
INFERENCE 
 According to paruvakaalam highest incident of 10 cases (50%) were noted in 
munpanikaalam and 4 cases (20%) were noted in Koothirkaalam, 3 cases (15%) were 
noted in kaarkaalam, 3 cases (15%) were noted in Pinpanikaalam. 
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6. DISTRIBUTION OF THINAI 
S.No THINAI NUMBER OF CASES PERCENTAGE (%) 
1 Kurinji 0                  0% 
2 Mullai 0 0% 
3 Marutham 5 12.5% 
4 Neithal 55 87.5% 
5 Paalai 0 0% 
 
 
              
 
INFERENCE 
 According to thinai the highest distribution 77.5% was noted in neithal, 12.5% in 
marutham, 10% in kurinji. 
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DISTRIBUTION OF MUKKUTRAM – VATHAM 
S.No VATHAM NUMBER OF CASES PERCENTAGE (%) 
1 Pranan 0 0% 
2 Abanan 48 80% 
3 Viyanan 60 100% 
4 Uthanan 0 0% 
5 Samanan 60 100% 
6 Nagan 0 0% 
7 Koorman 0 0% 
8 Kirukaran 0 0% 
9 Devathathan 0 0% 
10 Thananjeyan 0 0% 
  
                      
 
INFERENCE 
Out of 60 patients Pranan was affected in 0 patients (0%), Abanan was affected in 48 
pateints (80%), Viyanan was affected in 60 patients (100%), an Koorman ,kirukaran, 
Devadhathan, Dananjayan was affected in 0 patients (0%) 
 
 
 
R e s u l t s  a n d  O b s e r v a t i o n  |  
 
123 
DISTRIBUTION OF MUKKUTRAM – PITHAM 
 
 
 
 
INFERENCE 
 Out of 60 patients Analagam was affected in 28 patients (47%), Ranjagam was 
affected in 16 patients (27%), Sathagam was affected in 0 patients (0%), Aalosagam was 
affected in 0 patients (0%), pirasagam was affected in 0 patients ( 0%) 
 
 
 
 
S.No   PITHAM NUMBER OF CASES PERCENTAGE (%) 
1 Analagam 28 47% 
2 Ranjagam 16 27% 
3 Saathagam 0 0% 
4 Alosagam 0 0% 
5 Pirasagam 0 0% 
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DISTRIBUTION OF MUKKUTRAM – KABHAM 
 
S.No KABHAM NUMBER OF 
CASES 
PERCENTAGE (%) 
1 Avalambagam 0 0% 
2 Klethagam 0 0% 
3 Pothagam 28 47% 
4 Tharpagam 0 0% 
5 Santhigam 60 100% 
 
 
 
 
INFERENCE 
 
Out of 60 patients, Avalambagam, kilathagam and Tharpagam was affected in 0 
patients (0%), Santhigam was affected in 60 patients (100%), Potham was affected in 28 
patient (47%). 
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7. EZHU UDAL THATHUKAL 
 
S.No EZHU UDAL 
THATHUKAL 
 NUMBER OF 
CASES 
PERCENTAGE (%) 
1 Saaram 28 47% 
2 Senneer 16 27% 
3 Oon 60 100% 
4 Kozhupu 60 100% 
5 Enbu 60 100% 
6 Moolai 0 0% 
7 Sukkilam /Suronitham 0 0% 
  
  
 
 
 
INFERENCE 
Out of 60 patients, Saaram was affected in 28 patients (47%), Senneer was affected in 16 
patients (27%), Kozhupu was affected in 60 patient (100%), Enbu was affected in 60 
patients (100%). 
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8.  GUNAM 
 
S.No GUNAM  NUMBER OF 
CASES 
PERCENTAGE (%) 
1 Sathuva Gunam 0 0% 
2             Rasatha Gunam 60 100% 
3           Thamo Gunam 0 0% 
4            Total 60 100% 
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9. BODY CONSTITUTION 
 
 
S.No CONSTITUTION OF THE 
BODY 
 NUMBER OF 
CASES 
PERCENTAGE (%) 
1      VATHA THEGI 0 0% 
2      PITHTHA THEGI 0 0% 
3       KABA THEGI 0 0% 
4      THONTHA THEGI 60 100% 
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10.  CLINICAL FEATURES 
 
 
S.No    CLINICAL FEATURES  NUMBER OF 
CASES 
PERCENTAGE (%) 
1     PAIN IN THE LOWER 
BACK 
60 100% 
2 PAIN RADIATES TO BOTH 
THE LOWER LIMB 
49 81% 
3 UNABLE TO BEND 
FORWARD 
36 60% 
4 NUMBNESS IN BOTH THE 
LOWER LIMB 
24 40% 
5 PAIN AGGREVATES T 
 
HE AFTER SITTING FOR-
30 MINS 
51 85% 
6 PAIN AGGREVATES 
AFTER WALKING FOR-30 
MIN 
57 95% 
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11.   TRIGGERING  FACTORS 
 
 
S.No TRIGGERING FACTORS  NUMBER OF 
CASES 
PERCENTAGE (%) 
1   LIFTING HEAVY WEIGHT  4 6% 
2      RIDING MOTOR CYCLE 24 40% 
3      PSYCO-SOMATIC 4 6% 
4      ALCOHOL 6 9% 
5      SMOKING 5 8% 
6       SITTING KIND OF JOB 19 32% 
  
 
 
 
 Interference: 
 
 Among 60 Patients, 8% of them had Pelvic Infection, 37% of them had Lifting 
heavy weight kind of Job, 3% of them Riding Motor Cycle for long distance, 10% 
them had Psycho-somatic ailments, 13% of them had alcohol habit, 5% of them had 
smoking habit, 23% of them were in Sitting kind of job. 
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12.    SELECTION OF PATIENTS: 
 
 
 
 
Sl. No 
 
Treatment options 
 
No of patients 
1. Both Trial drugs 20 
2. Trial drug internal only 20 
3. External 20 
 
 
 
 
 
 
 
 
 
 
20                                              20 
 
Both Trial drugs 
 
Trial drug internal only 
 
20                                                           External 
 
 
 
 
 
 
 
 
Observation 
 
60 Cases were divided into III groups in such a way 20 cases in each group.  
Group – I :  In OPD 20 cases - moolayoga nirkundi thylam  and varmam theraphy.  
Group – II : In OPD 20 cases  - naga chendhuram and moolayoga nirkundi thylam. 
Group – III : In OPD 20 cases   - under both naga chendhuram, Moolayoga 
nirkundi thylam.  And varmam theraphy. 
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13.   IMPROVEMENT IN CLINICAL FEARTURES: 
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S. 
No 
Clinical features Before 
Treatment 
After 
treatment 
Percentage % 
1. Pain in the lower 
back 
60 2 96.6% 
2. Pain  radiates to both 
the lower limbs 
49 4 91.8% 
3. Unable to bend 
forward 
36 2 94.4% 
4. Numbness in both 
the lower limbs 
24 0 100% 
5. Pain aggravates after 
sitting for  30 min 
51 4 92.1% 
6. Pain aggravates after 
walking for  30 min 
57 7 87.7% 
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Group I (Moolayoga Nirkundi Thylam and Varmam) 
 
0
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15
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25
Percentage %
After treatment
Before Treatment
S. 
No 
Clinical features Before Treatment After treatment Percentage % 
1. Pain in the lower back 20 1 95% 
2. Pain  radiates to both 
the lower limbs 
                14 2 85.7% 
3. Unable to bend 
forward 
10 1 90% 
4. Numbness in both the 
lower limbs 
2 0 100% 
5. Pain aggravates after 
sitting for  30 min 
11 2 81.8% 
6. Pain aggravates after 
walking for  30 min 
19 4 78.9% 
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Group II (Naga chenduram  and Moolayoga nirkundi thylam) 
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S. 
No 
Clinical features Before Treatment 
After 
treatment 
Percentage % 
1. Pain in the lower back 20 1 95% 
2. Pain  radiates to both 
the lower limbs 
15 1 93.3% 
3. Unable to bend 
forward 
12 1 91.6% 
4. Numbness in both the 
lower limbs 
9 0 100% 
5. Pain aggravates after 
sitting for  30 min 
20 1 95% 
6. Pain aggravates after 
walking for  30 min 
19 2 89.4% 
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Group III (Naga chenduram , Moolayoga nirkundi thylam and varmam) 
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S. 
No 
Clinical features 
Before 
Treatment 
After 
treatment 
Percentage % 
1. Pain in the lower 
back 
20 0 100% 
2. Pain  radiates to both 
the lower limbs 
20 1 95% 
3. Unable to bend 
forward 
14 0 100% 
4. Numbness in both 
the lower limbs 
13 0 100% 
5. Pain aggravates after 
sitting for  30 min 
20 1 100% 
6. Pain aggravates after 
walking for  30 min 
19 1 89.4% 
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GROUP I ( MOOLAYOGA NIRKUNDI THYLAM AND VARMAM THERAPHY) 
 
S. No Op no Pain scale  Pain scale  
Before treatment 
  
After treatment 
  
1 3491 5 0 
2 5229 7 0 
3 5198 9 0 
4 5199 8 0 
5 5328 9 0 
6 6105 9 0 
7 8097 8 0 
8 9704 7 0 
9 9940 8                0 
10 5225 9 0 
11 5405 9 2 
12 5624 9 0 
13 5695 8 0 
14 8418 8 0 
15 5689 7 1 
16 6289 8 0 
17 6588 8 3 
18 6685 7 0 
19 8122 9 0 
20 121 8 4 
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GROUP II( NAGA CHENDURAM , MOOLAYOGA NIRKUNDI THYLAM) 
S. No Op no Pain scale  Pain scale  
Before treatment After treatment 
1 112 7 0 
2 8218 9 0 
3 4262 7 0 
4 6352 8 0 
5 5485 8 0 
6 5966 9 6 
7 6973 8 0 
8 7461 7 0 
9 1062 7 0 
10 4885 7 0 
11 5680 9 0 
12 6447 8 6 
13 94 8 0 
14 1336 6 2 
15 1432 8 0 
16 1416 8 0 
17 1855 9 0 
18 5822 7 0 
19 2892 8 0 
20 4399 7 0 
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GROUP III  
( NAGA CHENDURAM , MOOLAYOGA NIRKUNDI THYLAM AND 
VARMAM) 
S. No Op no Pain scale  Pain scale  
Before treatment 
  
After treatment 
  
1 2365 5 0 
2 2761 7 0 
3 6411 9 0 
4 6811 8 0 
5 70 9 0 
6 68 9 0 
7 9936 8 0 
8 1863 7 0 
9 2557 8                0 
10 3700 9 0 
11 4648 9 2 
12 4991 9 0 
13 5657 8 0 
14 5849 8 0 
15 6634 7 1 
16 8057 8 0 
17 8853 8 3 
18 721 7 0 
19 3298 9 0 
20 8755 8 4 
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EFFECT OF  GROUP  I 
 
Effect of therapy is assessed from the above tabulated data 
 
 
 
Sl. No Effect of therapy No of 
patients 
Percentage 
1. Marked improvement 17 85% 
2. Moderate improvement 3 15% 
3. Mild improvement 0 0% 
4. Poor improvement 0 0% 
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EFFECT OF GROUP II : 
 
Effect of therapy is assessed from the above tabulated data 
 
 
 
Sl. No Effect of therapy No of 
patients 
Percentage 
1. Marked improvement 12 60% 
2. Moderate improvement 6 30% 
3. Mild improvement 2 10% 
4. Poor improvement 0 0% 
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EFFECT  OF   G R O U P  I I I  : 
Effect of therapy is assessed from the above tabulated data 
 
 
Sl. No Effect of therapy No of 
patients 
Percentage 
1. Marked improvement 19 95% 
2. Moderate improvement 1 5% 
3. Mild improvement 0 0% 
4. Poor improvement 0 0% 
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OVERALL RESULTS AFTER TREATMENT 
 
Based  on  the  outcome  of  the  treatment,  all  the  40  patients  have  
been classified into 4 grades. The gradation is as follows, 
    Grade I (Marked Improvement) 
    Grade II (Moderate Improvement) 
    Grade III (Mild Improvement) 
                 Grade IV (Poor improvement) 
            
 
Sl. No Effect of therapy No of 
patients 
Percentage 
1. Marked improvement 48 80% 
2. Moderate improvement 10 17% 
3. Mild improvement 2 3% 
4. Poor improvement 0 0% 
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       BEFORE AND AFTER BLOOD INVESTIGATION FOR INTERNAL CASES (Group I) 
Sl. No. IP No. Name  Age & Sex BT & AT 
Investigation 
Blood Investigation Urine Investigation 
TC 
Cells / 
Cum m 
DC % ESR (mm) 
Hb gm 
Sug (R) 
Mg/dl 
AL Sug Dep 
P% L % E % ½ hr 1 hr 
1. 3491 SHANTHI 37/F BT 8600 45 48 7 25 42 12.4 95 Nil Nil Nil 
AT 8600 45 47 6 23 30 10 100 Nil Nil Nil 
2. 5229 GUNASEKAR 44/M BT 10300 64 32 4 6 15 11.2 133 Nil Nil Nil 
AT 10300 63 30 7 4 10 11.5 96 Nil Nil Nil 
3. 5198 LOGANAYAGI 55/F BT 8800 65 30 5 23 40 12 107 Nil Nil Nil 
AT 8500 56 39 5 14 30 13 90 Nil Nil Nil 
4. 5199 ANTONY 58/M BT 5100 53 36 11 7 15 15 109 Nil Nil Nil 
AT 8500 51 43 6 30 12 14.6 120 Nil Nil Nil 
5. 5328 RAVICHANTHARAN 36/M BT 7200 64 31 5 2 5 14.1 68 Nil Nil Nil 
AT 8300 62 37 1 2 5 14 95 Nil Nil Nil 
6. 6105 KALVARNIYAN 54/M BT 9200 60 35 5 17 30 11 84 Nil Nil Nil 
AT 8700 59 37 4 20 11 11.4 110 Nil Nil Nil 
7. 8097 KAMALA 55/F BT 7300 64 30 6 42 85 14.2 90 Nil Nil Nil 
AT 7800 58 41 1 12 8.5 11.5 118 Nil Nil Nil 
8. 9704 VELU 27/M BT 9600 46 48 6 9 15 16 89 Nil Nil 1-4 epi cells 
AT 10000 56 42 2 4 10 11.2 90 Nil Nil 1-4 epi cells 
9. 9940 Balaji 42/M BT 8300 58 34 8 2 10 15.7 95 Nil Nil Nil 
AT 9600 56 40 4 6 9 12.3 112 Nil Nil Nil 
10. 5225 VIMALA 36/F BT 8800 64 32 4 25 40 11.2 139 Nil Nil Nil 
AT 8800 60 36 2 30 12 10 99 Nil Nil Nil 
11. 5405 KAVITHA 45/F BT 8600 45 48 7 25 42 12.4 95 Nil Nil Nil 
AT 8600 45 47 6 23 30 10 100 Nil Nil Nil 
12. 5624 REVATHI 35/F BT 10300 64 32 4 6 15 11.2 133 Nil Nil Nil 
AT 10300 63 30 7 4 10 11.5 96 Nil Nil Nil 
13. 5695 JAI 35/M BT 8800 65 30 5 23 40 12 107 Nil Nil Nil 
AT 8500 56 39 5 14 30 13 90 Nil Nil Nil 
14. 8418 ESWARI 60/F BT 5100 53 36 11 7 15 15 109 Nil Nil Nil 
AT 8500 51 43 6 30 12 14.6 120 Nil Nil Nil 
15. 5689 SHARMILA 32/F BT 7200 64 31 5 2 5 14.1 68 Nil Nil Nil 
AT 8300 62 37 1 2 5 14 95 Nil Nil Nil 
16. 6289 GNANASELVAN 58/F BT 10500 66 31 3 25 40 13.1 80 Nil Nil Nil 
AT 10700 59 37 4 20 11 13.4 110 Nil Nil Nil 
17. 6588 SANKAR 45/M BT 7300 64 30 6 42 85 14.2 90 Nil Nil Nil 
AT 7800 58 41 1 12 8.5 11.5 118 Nil Nil Nil 
18. 6685 MUTHAMMAL 48/F BT 9900 47 45 8 22 40 12.5 89 Nil Nil Nil 
AT 10000 56 42 2 4 10 12.7 90 Nil Nil Nil 
19. 8122 SAKAYARAJ 43/M BT 8300 58 34 8 2 10 15.7 95 Nil Nil Nil 
AT 9600 56 40 4 6 9 12.3 112 Nil Nil Nil 
20. 121 GEETHA 43/F BT 8800 64 32 4 25 40 11.2 139 Nil Nil Nil 
AT 8800 60 36 2 30 12 10 99 Nil Nil Nil 
 BEFORE AND AFTER BLOOD INVESTIGATION FOR INTERNAL CASES(Group II) 
 
Sl. No. IP No. Name Age & Sex BT & AT 
Investigation 
Blood Investigation Urine Investigation 
TC 
Cells / 
Cum m 
DC % ESR (mm) 
Hb gm 
Sug (R) 
Mg/dl 
AL Sug Dep 
P% L % E % ½ hr 1 hr 
1. 112 NEELAMEGAM 44/M 
BT 8700 46 47 7 4 2 14.0 95 Nil Nil Nil 
AT 8600 45 47 6 5 2 14.4 100 Nil Nil Nil 
2. 8218 VIMALA 36/F 
BT    7300 64 32 4 6 8 11.2 133 Nil Nil Nil 
AT 7500 63 30 7 4 10 11.5 96 Nil Nil Nil 
3. 4262 LEELA 58/F 
BT 6400 65 30 5 23 40 12 107 Nil Nil Nil 
AT 7000 56 39 5 14 30 13 90 Nil Nil Nil 
4. 6352 SUMATHI  
BT 7000 63 30 3 13 21 10.6 90 Nil Nil Nil 
AT 7800 51 43 6 30 12 11 120 Nil Nil Nil 
5. 5485 VIMALA 35/F 
BT 7100 64 31 5 2 5 12.1 68 Nil Nil Nil 
AT 7800 62 37 1 2 5 12 95 Nil Nil Nil 
6. 5966 SEKAR 48/M 
BT 6400 60 35 5 17 30 13.4 84 Nil Nil   1-4 epi cells 
AT 6500 59 37 4 20 11 13 110 Nil Nil 1-4 epi cells 
7. 6973 MANJULA 55/F 
BT 6300 64 30 6 42 85 11.2 90 Nil Nil Nil 
AT 7000 58 41 1 12 8.5 11.5 118 Nil Nil Nil 
8. 7461 MUNIYAMA 46/F 
BT 9600 46 48 6 9 15 16 89 Nil Nil Nil 
AT 10000 56 42 2 4 10 11.2 90 Nil Nil Nil 
9. 1062  MUMDHAJ 49/F 
BT 8300 58 34 8 2 10 15.7 95 Nil Nil Nil 
AT 9600 56 40 4 6 9 12.3 112 Nil Nil Nil 
10. 4885 SITHIRASENAN 38/M 
BT 8800 64 32 4 25 40 14.2 139 Nil Nil Nil 
AT 8800 60 36 2 30 12 14 99 Nil Nil Nil 
11. 5680 PUVANESHWARI 52/F 
BT 8600 45 48 7 25 42 12.4 95 Nil Nil Nil 
AT 8600 45 47 6 23 30 10 100 Nil Nil Nil 
12. 6447 RANI 56/F 
BT 21310 56 34 2 6 15 14.2 122 Nil Nil Nil 
AT 20100 57 32 5 4 10 13.3 110 Nil Nil Nil 
13. 94 JAYARAMAN 50/M 
BT 6220 59 30 1 23 40 15 107 Nil Nil 1-3 pus cells 
AT 6500 56 39 5 14 30 13 90 Nil Nil 1-3 pus cells 
14. 1336 MUNIRBATSHA 40/M 
BT 5100 53 36 11 7 15 15 109 Nil Nil Nil 
AT 8500 51 43 6 30 12 14.6 120 Nil Nil Nil 
15. 1432 PRAMILA 50/F 
BT 7200 64 31 5 2 5 14.1 68 Nil Nil Nil 
AT 8300 62 37 1 2 5 14 95 Nil Nil Nil 
16. 1416 RANI 52/F 
BT 10500 66 31 3 25 40 13.1 80 Nil Nil Nil 
AT 10700 59 37 4 20 11 13.4 110 Nil Nil Nil 
17. 1855 KANAMAI 37/F 
BT 8700 64 30 6 42 85 14.2 90 Nil Nil Nil 
AT 7800 58 41 1 12 8.5 11.5 118 Nil Nil Nil 
18. 5822 SATHYAIYAN 53/M 
BT 11200 47 45 8 22 40 12.5 89 Nil Nil Nil 
AT 10000 56 42 2 4 10 12.7 90 Nil Nil Nil 
19. 2892 JAYARAMAN 50/M 
BT   7900 58 34 8 2 10 15.7 95 Nil Nil Nil 
AT 7600 56 40 4 6 9 12.3 112 Nil Nil Nil 
20. 4399 SANKARI 60/F 
BT 4800 64 32 4 25 40 11.2 139 Nil Nil Nil 
AT 5000 60 36 2 30 12 10 99 Nil Nil Nil 
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Sl. No. IP No. Name Age & Sex BT & AT 
Investigation 
Blood Investigation Urine Investigation 
TC 
Cells / 
Cum m 
DC % ESR (mm) 
Hb gm 
Sug (R) 
Mg/dl 
AL Sug Dep 
P% L % E % ½ hr 1 hr 
1. 3226 MANJULA 40/F 
BT 8900 55 41 5 10 20 13 98 Nil Nil 1-4 pus cells 
AT 8200 54 43 3 3 6 13 110 Nil Nil 1-4 pus cells 
2. 3589 VANATHI 58/F 
BT 8100 57 40 3 10 22 10 109 Nil Nil Nil 
AT 8000 54 41 4 2 4 10.5 95 Nil Nil 1-2 epi cells 
3. 3526 MEENA 50/F 
BT 7400 56 39 5 26 50 8.8 118 Nil Nil 1-2 epi cells 
AT 7000 55 38 4 9 14 9.5 110 Nil Nil Nil 
4. 3551 MADHAVI 50/F 
BT 8500 68 26 6 15 35 11.2 70 Nil Nil Nil 
AT 8000 60 32 3 4 12 11.6 85 Nil Nil Nil 
5. 3847 MOHAMED KASIM 34/M 
BT 8900 55 41 4 15 28 12.4 94 Nil Nil 2-3 pus cells 
AT 8000 54 40 4 15 20 11 110 Nil Nil Nil 
6. 4380 VALARMATHI 47/F 
BT 7800 44 51 5 8 15 13.6 82 Nil Nil Nil 
AT 8000 45 40 3 6 12 13.6 82 Nil Nil Nil 
7. 4468 JANARTHANAN 41/M 
BT 9000 66 30 4 10 24 10.4 119 Nil Nil 1-2 epi cells 
AT 8000 54 36 5 5 10 12.6 120 Nil Nil  
8. 4307 JAYANTHI 44/F 
BT 9700 63 30 7 50 72 10.6 82 Nil Nil 1-2 epi cells 
AT 8800 60 36 2 2 4 10 99 Nil Nil Nil 
9. 4799 MANGALALAKMI 44/F 
BT 10200 68 27 5 6 16 12.8 97 Nil Nil 1-4 pus cells 
AT 8000 62 34 4 3 6 13 94 Nil Nil Nil  
10. 4878 MEENA 58/F 
BT 8400 61 32 7 26 38 13 83 Nil Nil 2-3 pus cells 
AT 7000 56 40 4 5 4 13.4 90 Nil Nil 2-3 pus cells 
11. 5022 PUSHPA 58/F 
BT 7200 49 45 6 20 44 9.6 93 Nil Nil Nil 
AT 8000 54 43 3 18 9 10 110 Nil Nil Nil 
12. 835 CHITHARA 45/F 
BT 7980 58 28 5 12 27 13.1 120 Nil Nil 6-8epi cells 
AT 8000 63 30 7 4 10 11.5 96 Nil Nil 2-3epi cells 
13. 1815 GOWSALA 60/F 
BT 8500 60 37 3 2 6 12.5 77 Nil Nil Nil 
AT 8500 56 39 5 32 11 13 90 Nil Nil Nil 
14. 6738 SATHYABAMA 36/F 
BT 7200 52 43 5 5 16 12.6 170 Nil Nil Nil 
AT 8500 51 43 6 30 12 12.6 120 Nil Nil Nil 
15. 9290 SHANTHI 38/F 
BT 8400 54 41 5 10 18 11 74 Nil Nil Nil 
AT 8300 62 37 1 30 10 11.5 95 Nil Nil Nil 
16. 7373 NASIYA 34/F 
BT 9200 60 35 5 17 30 11 84 Nil Nil 
1-2 epi cells 
AT 8700 59 37 4 20 11 11.4 110 Nil Nil 
1-2 epi cells 
17. 5240 PRAMILA 47/F 
BT 7800 56 40 4 32 8 10 108 Nil Nil Nil 
AT 7800 58 41 1 12 8.5 11.5 118 Nil Nil Nil 
18. 9578 VALARMATHI 50/F 
BT 9500 59 38 3 18 9 11 82 Nil Nil Nil 
AT 10000 56 42 2 4 10 11.2 90 Nil Nil Nil 
19. 9587 TAMIL ARASI 40/F 
BT 7500 60 34 6 15 58 9 109 Nil Nil Nil 
AT 9600 56 40 4 6 9 12.3 112 Nil Nil Nil 
20. 524 DHILIBAI 45/F 
BT 9400 53 37 4 26 39 9.4 83 Nil Nil Nil 
AT 9100 60 36 2 30 12 10 99 Nil Nil Nil 
 LFT & RFT FOR GROUP III( NAGA CHENDURAM , MOOLAYOGA NIRKUNDI THYLAM AND VARMAM) 
 
 
 
LFT 
 
RFT 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
BEFORE 
TREATMENT 
AFTER T 
REATMENT 
S. 
NO 
OP. 
NO 
SGOT SGPT 
TOTAL 
PROTEINS 
TOTAL 
BILIRUBIN 
SGOT SGPT 
TOTAL 
PROTEINS 
TOTAL 
BILIRUBIN 
UREA CREATININE UREA 
CREATIN
INE 
 1 112 25 44 6.4 0.3 28 48 6.9 0.6 23 0.5 22 0.5 
2 8218 35 36 6.3 0.8 38 40 6.7 0.7 24 0.3 22 0.3 
3 4262 18 18 6.9 0.6 18 18 7.1 0.7 35 0.8 26 0.5 
4 6352 24 42 6.9 0.6 29 46 7.1 0.7 26 0.5 24 0.4 
5 5485 32 38 6.8 0.9 35 44 7.1 1.0 24 0.5 21 0.5 
6 5966 21 25 7.4 0.4 25 28 7.6 0.7 28 0.5 24 0.5 
7 6973 26 37 7.2 0.4 28 40 7.6 0.6 28 0.4 28 0.3 
8 7461 31 42 7.1 0.3 35 36 7.4 0.4 25 0.6 22 0.6 
9 1062 36 32 6.9 0.9 38 38 6.5 0.8 24 0.5 26 0.5 
10 4885 28 46 6.9 0.9 31 24 6.5 0.8 19 0.6 14 0.8 
11 5680 18 48 6.9 0.9 25 50 6.8 0.7 22 0.5 30 0.5 
12 6447 58.6 100 8.35 1.48 56 100 6.9 1.40 31.2 0.60 28 0.30 
13 94 15.2 19.3 6.4 0.98 14.8 48 6.5 1.0 26 0.89 24 0.80 
14 1336 25 42 7.4 0.4 29 46 7.6 0.6 27 0.7 24 0.5 
15 1432 28 38 7.4 0.8 20 32 7.6 0.6 33 0.5 30 0.5 
16 1416 35 30 7.2 0.4 21 25 7.4 0.5 29 0.7 23 0.9 
17 1855 36 32 6.1 0.9 38 28 6.4 0.8 24 0.5 30 0.4 
18 5822 28 40 7.3 0.8 32 48 7.6 0.5 28 0.5 27 0.5 
19 2892 24 27 7.1 0.6 29 25 7.4 0.7 26 0.4 24 0.4 
20 4399 32 37 7.0 0.8 35 39 7.2 0.9 31 0.5 32 0.5 
                                        LFT & RFT FOR GROUP III( NAGA CHENDURAM , MOOLAYOGA NIRKUNDI THYLAM 
 
 
 
 
LFT 
 
RFT 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
BEFORE 
TREATMENT 
AFTER 
TREATMEN
T 
S 
NO 
OP NO SGOT SGPT 
TOTAL 
PROTEINS 
TOTAL 
BILIRUBIN 
SGOT SGPT 
TOTAL 
PROTEINS 
TOTAL 
BILIRUBIN 
UREA 
CREATININ
E 
UREA 
CREA
TININ
E 
1 3226 25 44 6.5 0.4 28 48 6.8 0.6 21 0.5 22 0.5 
2 3589 35 36 6.7 0.3 38 40 6.8 0.6 19 1.0 20 0.4 
3 3526 29 41 6.9 0.9 34 45 6.8 0.8 35 0.7 23 0.5 
4 3551 28 42 7.4 0.8 29 46 7.1 0.7 30 0.8 24 0.4 
5 3847 32 38 7.2 0.9 35 44 7.4 1.0 23 0.5 21 0.5 
6 4380 21 25 7.4 0.8 25 28 7.2 0.6 22 0.5 24 0.5 
7 4468 26 37 7.4 0.6 28 40 7.8 0.5 23 0.3 28 0.3 
8 7461 31 42 7.6 0.5 35 36 6.8 0.3 33 0.5 22 0.5 
9 5680 36 32 6.4 0.3 38 38 6.7 0.5 27 0.5 26 0.5 
10 6447 28 46 6.2 0.5 32 40 6.4 0.4 26 0.5 20 0.5 
11 94 18 48 7.4 0.4 25 50 7.2 0.6 26 0.5 30 0.5 
12 835 30.5 32.9 8.04 0.86 20 29 7.9 1.0 14.7 0.57 15 0.3 
13 1815 14.5 9.8 7.3 0.27 14.5 10 7.1 0.37 17.6 0.67 18 0.8 
14 6738  42 6.6 0.4 29 46 6.2 0.8 18 0.4 24 0.5 
15 9290 28 38 6.5 0.8 20 32 6.9 0.5 28 0.5 30 0.5 
16 7373 35 30 6.4 0.8 38 34 6.2 0.4 32 0.5 30 0.5 
17 5240 36 32 6.7 0.8 38 28 7.1 0.6 28 0.7 30 0.4 
18 9578 28 40 6.4 0.4 32 48 6.2 0.8 28 0.5 27 0.5 
19 9587 24 27 6.5 1.0 16 13 6.7 1.0 28 0.4 16 1.0 
20 524 21.2 16.1 6.8 0.47 15.3 15.2 7.1 0.37 10.6 0.58 10 0.5 
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STATISTICAL ANALYSIS 
CLINICAL PROGNOSIS 
Treatment for : THANDAGAVATHAM  
The most popular non parametric statistical tool, namely, McNemar Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Pain in the lower back 60(100) 2(3.5)** 
2. Pain  radiates to both the 
lower limbs 
49(79) 4(7)** 
3. Unable to bend forward 36(60) 2(3.5)** 
4. Numbness in both the lower 
limbs 
24(40) 0(0)** 
5. Pain aggravates after sitting 
for  30 min 
51(85) 4(7)** 
6. Pain aggravates after 
walking for  30 min 
57(95) 7(12)** 
 
Mc Nemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 60 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing 
of clinical features among the patients for the treatment of Thandagavatham. Hence it 
is concluded that the treatment was effective and significant. 
Treatment for Disease Name: 
The most popular non parametric statistical tool, namely, McNemar Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
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Group I (Moolayoga Nirkundi Thylam And Varmam) 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Pain in the lower back 20(100) 1(5)** 
2. Pain  radiates to both the 
lower limbs 
14(70) 2(10)** 
3. Unable to bend forward 10(50) 1(5)** 
4. Numbness in both the lower 
limbs 
2(10) 0(0)* 
5. Pain aggravates after sitting 
for  30 min 
11(55) 2(10)** 
6. Pain aggravates after 
walking for  30 min 
19(95) 4(20)** 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing 
of clinical features among the patients for the treatment of Thandaga vatham. Hence it is 
concluded that the treatment was effective and significant. 
Treatment for Disease Name: 
The most popular non parametric statistical tool, namely, McNemar Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
Group II (Naga Chenduram  And Moolayoga Nirkundi Thylam) 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Pain in the lower back 20(100) 1(5)** 
2. Pain  radiates to both the lower limbs 15(75) 1(5)** 
3. Unable to bend forward 12(60) 1(5)** 
4. Numbness in both the lower limbs 9(45) 0(0)** 
5. Pain aggravates after sitting for  30 min 20(100) 1(5)** 
6. Pain aggravates after walking for  30 min 19(95) 2(10)** 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
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Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing 
of clinical features among the patients for the treatment of Thandaga vatham. Hence it is 
concluded that the treatment was effective and significant.  
Group III (Naga Chenduram, Moolayoga Nirkundi Thylam And Varmam) 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Pain in the lower back 20(100) 9(45)** 
2. Pain  radiates to both the 
lower limbs 
20(100) 1(5)** 
3. Unable to bend forward 14(70) 0(0)** 
4. Numbness in both the lower 
limbs 
13(65) 0(0)** 
5. Pain aggravates after sitting 
for  30 min 
20(100) 1(5)** 
6. Pain aggravates after 
walking for  30 min 
19(95) 1(5)** 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant reducing 
of clinical features among the patients for the treatment of Thandaga vatham. Hence it is 
concluded that the treatment was effective and significant. 
LFT For Group III( Naga Chenduram , Moolayoga Nirkundi Thylam And Varmam)  
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 SGPT 38.66±16.65 40.15±17.07 0.479 
2 SGOT 28.79±9.34 30.24±9.07 0.196 
3 Total Proteins 6.99±0.49 7.09±0.42 0.479 
4 Total bilirubin 0.70±0.29 0.73±0.22 <0.001  
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
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LFT For Group III (Naga Chenduram , Moolayoga Nirkundi Thylam) 
  
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 SGPT 34.94±9.74 35.51±11.94 0.651 
2 SGOT 27.71±5.90 28.49±7.93 0.482 
3 Total Proteins 6.91±0.50 6.92±0.47 0.967  
4 Total bilirubin 0.61±0.23 0.62±0.21 0.816  
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically significant. 
 
 
RFT For Group III (Naga Chenduram, Moolayoga Nirkundi Thylam And Varmam)  
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 26.66±3.88 25.05±4.11 0.074 
2 Creatinine 0.54±0.14 0.51±0.16 0.181 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant.  
 
 
RFT For Group III (Naga Chenduram , Moolayoga Nirkundi Thylam) 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 24.49±6.32 23.00±5.52 0.224 
2 Creatinine 0.55±0.15 0.50±0.15 0.347 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically significant. 
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S.No. BT PAIN 
Scale 
AT PAIN 
Scale 
1 5 0 
2 7 0 
3 9 0 
4 8 0 
5 9 0 
6 9 0 
7 8 0 
8 7 0 
9 8 0 
10 9 0 
11 9 2 
12 9 0 
13 8 0 
14 8 0 
15 7 1 
16 8 0 
17 8 3 
18 7 0 
19 9 0 
20 8 4 
 
Software: spss17 version 
Variables: PAIN Scale – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.46 
Before and after treatment mean difference: 7.50 ± 1.50. 
P Value (2 tailed): p<0.001. 
 
Inference:  
Since the P value is highly significant (<0.001). So there is significant reducing of 
PAIN Scale among the patients for the treatment of Thandaga Vatham . Hence it is concluded 
that the treatment was effective and significant. 
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S.No. BT PAIN 
Scale 
AT PAIN 
Scale 
1 7 0 
2 9 0 
3 7 0 
4 8 0 
5 8 0 
6 9 6 
7 8 0 
8 7 0 
9 7 0 
10 7 0 
11 9 0 
12 8 6 
13 8 0 
14 6 2 
15 8 0 
16 8 0 
17 9 0 
18 7 0 
19 8 0 
20 7 0 
 
Software: spss17 version 
Variables: PAIN Scale – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.82 
Before and after treatment mean difference: 7.05 ± 1.90. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant reducing of 
PAIN Scale among the patients for the treatment of Thandaga vatham. Hence it is concluded 
that the treatment was effective and significant. 
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S.No. BT PAIN 
Scale 
AT PAIN 
Scale 
1 5 0 
2 7 0 
3 9 0 
4 8 0 
5 9 0 
6 9 0 
7 8 0 
8 7 0 
9 8 0 
10 9 0 
11 9 2 
12 9 0 
13 8 0 
14 8 0 
15 7 1 
16 8 0 
17 8 3 
18 7 0 
19 9 0 
20 8 4 
 
Software: spss17 version 
Variables: PAIN Scale – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.470 
Before and after treatment mean difference: 7.50 ± 1.50. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant reducing of 
PAIN Scale among the patients for the treatment of Thandaga vatham. Hence it is concluded 
that the treatment was effective and significant. 
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DISCUSSION 
Low back ache is a very common problem and has a ubiquitous distribution. 
Among  the  galaxy of causative  factors both spinal and extra spinal, the common cause 
of low backache seems to be the lumbar disc disease. Bad posture plays a very significant 
role in the genesis of  this disease.
e
This is a degenerative disorder of the lumbar spine 
characterised clinically by an insidious onset of pain and stiffness and radiologically by 
osteophyte formation.
 
The retrospective review of the disease Thandaga vaatham mentioned in Siddha 
literatures begins from the correlation of it to the signs and symptoms of the disease 
lumbar spondylosis.   The drugs which possess anti-vaatha property as mentioned in 
Siddha literature were selected and the trial drugs were prepared by the Author in the 
Gunapadam practical laboratory of Goverment Siddha Medical College, after getting 
proper authentication of raw drugs from the Medicinal Botany Department under the 
supervision of the members of the teaching faculty and guided by the Head of the 
Department of Sirappu Maruthuvam of the Goverment Siddha Medical College, Chennai 
– 106 
60 patients of both genders were recruited for this study. Among 60 patients, 20 
patients were treated with Varmam treatment along with the External trial drugs, 20 
patients trial Medicine and External trial drugs and remaining 20 patients Varmam, 
External trial drugs trial Medicine 
The patients were examined based on Siddha and as well as modern aspects. All 
the  necessary investigations were made during the study. The results obtained from their 
studies were discussed below for better conclusion. 
 
AGE DISTRIBUTION: 
 Majority of the case that is 43% were in the 4th decade, 30% were in the 5 decade, 
27% were in the 3rd decade. This present study reports coincides with the recent 
incidence that indicates that the onset is most frequent during third,fourth and fifth 
decades of life .About 80% of all patients developing this disease between the ages 30 -
50. 
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SEX DISTRIBUTION : 
Among the 60 patients selected for this study, 30 % were males and 70 % were 
females. This indicates the prevalence of this disease more in females. 
 
OCCUPATIONAL STATUS : 
Mixed categories of people are affected, from housewife to office worker. 
Occupation of the patients is also an the impotant cause for the lumbar spondylosis. The 
study revealed that out of 60 patients, 40 % of them were homemakers,23.3% of them are 
Computer Based Job and tailors. 36.6% of them are others (Cooli, Business, Teacher, 
Engineer).This reveals that prolong sitting, weight bearing leads to lumbar pain. 
SOCIO ECONOMIC STATUS:  
The reported patients the datas revealed  that 17.5% of the patients were from low 
income group , 62.5% of them from middle income group and only 20% of them came 
from high income group (table3),this condition invariably affects all socio economic 
groups. 
 
CHRONICITY OF ILLNESS: 
In 35% of the patients duration of illness is between 1 months to 1 year. 26.6% of 
the patients had duration of  1-2years .20% of the patients had duration of  2-5 years 20% 
in 5-10 years,16.6%in  10 years(table 14). The clinical study reveals that the onset is 
gradual  in  90% of the patients and sudden  in 10% of patients. 
 
NAADI: 
              Examination in all the 60 patients showed that vathapitham naadi was felt in 
75% of the cases, 20% of them had Pithavatham naadi,5% of the cases had pitha kabam 
 
THINAI DISTRIBUTION: 
 The statistical data of this study reveals that 87.5% of the patients reported from 
Neithal thinai and 12.5% of them were from Marutham Thinai (Table 7). Siddha 
literatures say Vatham diseases are more prevalent in Neithal Thinai.= 
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KAALAM DISTRIBUTION: 
Out of 60 patients, 60  were reported in pitha kaalam  
 
DIET HABIT.   
Among 20 patients, 14  patients eat vegetarian food and others eat mixed diet. 
Diet doesn’t seem to possess any influence over the disease. 
 
On clinical manifestations:  
All of my patients had pain in lumbar region, 81% patient had  Pain  radiates to 
both the lower limbs. 
  
Mukkutram: 
Vadham  
Among the 60 cases Abanan - 80%  affected  Samanan and Viyanan were affected in all 
the cases. 
Pitham  
Ranjagam was found affected in 27% of cases, Anarpitham was affected in 47%  the 
cases. 
Kabam: 
 Avambagam -100 Pothagam were found to be affected in 47% f the cases and then 
sathagam were found to be affected in 100%of the cases. 
 
UDAL KATTUGAL: 
Among the 60 patients, Oon, Kozhupu, Enbu were affected in all the 100% cases, Saaram 
was affected in 47% cases and Senner was affected in 28% cases. 
 
 
 
RADIOGRAPHIC  STUDIES  
The radiographic studies of the cases showed narrowed joint space and presence 
of osteophytes. The trial drug showed improvement in prognosis of the disease clinically. 
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The total study showed that out of the 60 patients (55% of the patients had good 
improvement in the clinical assessment, 27.5% of them had moderate improvement, 
17.5% of them had mild improvement. 
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SUMMARY 
I have to summarize this study with the following highlights.  The 60 case of  
Thandagavatham   were diagnosed clinically. Among 60 patients, 20 patients were treated with 
Varmam treatment along with the External trial drugs, 20 patients trial Medicine and External 
trial drugs and remaining 20 patients Varmam, External trial drugs trial Medicine in outpatient  
for 48 days in Department of Sirappu Maruthuvam of the Government Siddha Medical College, 
Chennai – 106 
The Study Protocol was approved by Institutional Ethics committee (GSMC-CH-ME-
2015/015).Before initiating the clinical trial, it was registered in Clinical Trials Registry of India 
and the registration number Ref No Is: CTRI/2017/05/008542. 
The various Siddha methods of examination of the disease were carried out and the data 
were recorded in the prescribed Proforma for the 60 selected cases. 
During the period of treatment all the patients are advised for Pathiyam (specific dietary 
regimen chart for the disease given to each patient. 
Laboratory investigations are done periodically for all the cases before and after 
treatment and radiological investigations are done for all the cases before treatment. 
The observations made during the clinical study showed that internal and external drugs 
are effective in relieving the pain in Thandagavatham patients. During the study period, there 
was no adverse event reported. As per the Siddha Literature and recent research articles, the 
ingredients of the trial drugs was found to have anti inflammatory, immunomodulator ,anti-
oxidant, analgesic properties owing to the disease manifestations. 
The mean pain score before treatment was 7.50, after treatment it was reduced to 1.50.  
Hence this study reveals that patients treated with trial drugs and varmam showed good 
enhancement when compared to those who are  treated only with trial drugs. Statistical analysis 
showed significant reduction in the pain score and questionnaire before and after treatment. 
The outcome of the trial medicine was assessed by grading method and the results were 
as follows:  
                                    Good improvement    -       patients (80%) 
   Moderate improvement  -       patients (17%) 
   Mild improvement       -       patients (3%) 
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CONCLUSION 
 Low back ache is a very common problem and has a ubiquitous distribution.  Among  the  
galaxy of causative  factors both spinal and extra spinal, the common cause of low 
backache seems to be the lumbar disc disease. Bad posture plays a very significant role in 
the genesis of this disease.  
 Thandagavatham  is mainly due to derangements of Vadha humour. 
 The Naga Chendhuram reveals no toxicity in the preclinical studies and hence proved to 
be safe for human administration. 
 The clinical trial proves the efficacy of her trail drugs by reducing the clinical signs and 
symptoms like radiating pain, numbness, restricted movements and provides better 
improvement. The study results show that of 8 (20%) of them had mild improvement, 12 
(30%) of them had moderate improvement and 20 (50%) of them had good improvement 
after treatment. Thus these results revealed good relief from the disease after treatment. 
 The preparation of trial medicine is economical. The trial Medicines were prepared from 
easily available ingredients and the palatability of medicine is better and the dosage is 
also convenient.  Patients treated with trial drugs and Varmam showed good 
enhancement when compared to those who were  treated only with trial drugs. When 
these affected individuals get a better management with this trial drug and Varmam, it 
would be a great useful medication.  
 In the present study there was no adverse effect were reported in clinical trial. Hence the 
drugs were proven for their safety. The clinical trial conducted in selected patients was 
satisfactory encouraging. Further studies may be taken up to establish the efficacy of the 
drug. 
 Therefore the author concluded that the trial medicine NAGA CHENDHURAM 
(INTERNAL) and MOOLAYOGA NIRKUNDI THYLAM (EXTERNAL) WITH 
VARMAM THERAPHY can give better solutions for Thandagavatham (Lumbar 
Spondylosis). 
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GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbar spondylosis) with the
evaluation of Siddha trial drugs “Naga Chendurum” (Internal), “Moolayoga Nirkundi
thylam” (external) and Varmam Therapy.
FORM l - SCREENING AND SELECTION PROFORMA
1. OP NO: .................................................................
2. NAME: ………………………………………….
3. AGE: ………       4.GENDER: ………….......
5. OCCUPATION: ………………………………..      6.INCOME:   …………………
7. ADDRESS: ……………………………………
……………………………………
……………………………………
8. CONTACT NO:    ……………………………………
 INCLUSION CRITERIA:
• Age 35-60 years Yes / No
• Patient with appropriate symptoms like lower back pain radiates to the lower extremities
anteriorly, Tenderness, numbness, limitation of lower backmovements. Yes/No
• Patients who are willing to undergo radiological investigation and Laboratory
investigations. Yes / No
• Patients who are willing to sign the informed consent stating that she will conscientiously
stick to the treatment during 12 days but can opt out of the trial of her own conscious discretion.
Yes / No
EXCLUSION CRITERIA
History of
• Traumatic condition
• Inter vertebral disc prolapse
• Ankylosing spondylosis
• Spondylolesthesis
• Neoplasm
• Congenital anamolies
• Gibbus  deformity
• Cardiac diseases
• Pregnancy women and lactating mother
• Patients with any other serious systemic illness
ADMITTED TO TRIAL:
YES                        NO
Date:
Station:
Signature of the Guide Signature of the Investigator:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbar spondylosis) with the
evaluation of Siddha trial drugs “Naga Chendhuram” (Internal), “Moolayoga Nirkundi
thylam” (external) and Varmam Therapy.
FORM lI -HISTORY TAKING PROFORMA
1. SERIAL NO OF THE CASE: …….   2.OP NO: ....................................................
3. NAME: ………………………………………… 4. AGE: …….. 5. GENDER: ……..
5. OCCUPATION: ………………………………      6. INCOME:   …………………..
7.COMPLAINTS & DURATION:
8.PERSONAL HISTORY:
PERSONAL HABITS YES NO IF YES, SPECIFY
DURATION/QUANTITY
Smoking
Tobacco Chewing
Alcoholism
Narcotic drugs
9. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY
10. DIETARY HABIT:
 1.Vegetarian
2.Non-vegetarian
11. FAMILY HISTORY:
Whether this problem runs in family?
1. Yes                               2.No
If yes, mention the relationship of affected person(s) ---------------------
History of previous investigations if any ------------------------------
Date:
Station:
Signature of the Guide: Signature of the Investigator:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbarspondylosis) with the
evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga Nirkundi
thailam” (external) and Varmam Therapy.
FORM III – CLINICAL ASSESSMENT PROFORMA
1. SERIAL NO: …………………
2.OP / IP NO: ......................................
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................
GENERAL EXAMINATION:
Height (cms) : ………………………….
Weight (kg) : ………………………….
Temperature(°F) : ………………………….
Pulse rate(/min) : ………………………….
Heart rate(/min) : ………………………….
Respiratory rate(/min) : ………………………….
Blood pressure(mm/Hg)  : ………………………….
Present Absent
Pallor
Jaundice
Cyanosis
Lymphadenopathy
Pedal edema
Clubbing
Jugular vein pulsation
SYSTEMIC EXAMINATION
CardioVascular System : ………………………….
Respiratory system : ………………………….
Gastro-intestinal system : ………………………….
Central Nervous System : ………………………….
Urogenital system : ………………………….
Endocrine System : ………………………….
SIDDHA SYSTEM OF EXAMINATIONS:
1. THEGI:  [BODY CONSTITUTION]
1. Vatha udal
2. Pitha udal
3. Kaba udal
4. Thontha udal
2. NILAM:  [LAND WHERE PATIENT LIVED MOST]
1. Kurinji
2. Mullai
3. Marutham
4. Neithal
5. Paalai
3. KAALAM:
1. Kaar kaalam 4.Pinpani kaalam
2. Koothir kaalam 5. Ilavenil kaalam
3. Munpani kaalam 6.Muthuvenil kaalam
4. GUNAM:
1.Sathuvam 2.Raasatham 3.Thaamatham
5. IMPORIGAL (SENSORY ORGANS):
                                                                        Normal/Affected
Mei - -----------------------------------------------
Vaai -----------------------------------------------
Kann --------------------------------------------------------
Mukku -------------------------------------------------------
Sevi ------------------------------------------------
6. KANMENDHIRIYAM (MOTOR ORGANS):
Kai ----------------------------------
Kal ------------------------------------
Vaai ------------------------------------
Eruvai ----------------------------------
Karuvaai ---------------------------------
7. KOSANGAL (SHEATH):
Annamaya kosam ------------------------
Pranamaya kosam --------------------------
Manomaya kosam -------------------------------
Vignana maya kosam -----------------------------
Anandamaya kosam -------------------------------
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI, AZHAL, IYAM)
A) VALI
 Pranan –--------------------
Abanan --------------------
Samanan ---------------------
Uthanan ------------------------
Vyanan -------------------------
Naagan ---------------------------
Koorman -----------------------------
Kirukaran ----------------------------
Devathathan ----------------------------
Dhananjayan ----------------------------
B) AZHAL
Analakam --------------------
Ranjakam ---------------------
Sathakam -----------------------
Prasakam ------------------------
Alosakam --------------------------
C) IYAM
Avalambagam ------------------------
Kilethagam ---------------------------
Pothagam ------------------------------
Tharpagam ----------------------------
Santhigam ------------------------------
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS)
Saram -----------------------
Senneer -------------------
Oon --------------------------
Koluppu -----------------------
Enbu ---------------------------
Moolai ---------------------------
Sronitham -------------------------
10. ENVAGAI THERVU:
I. NAADI: [PULSE PERCEPTION]
II. SPARISAM: [PALPATION]
III. NAA: [TONGUE]
IV.NIRAM: [COMPLEXION]
1. Vadham
2. Pitham
3. Kabam
V.MOZHI: [VOICE]
1. High Pitched
2. Low Pitched
3. Medium Pitched
VI.VIZHI: [EYES]
VII. MALAM: [BOWEL HABITS / STOOLS]
Niram
Irugal
Ilagal
Others
 VIII. MOOTHIRAM [URINE EXAMINATION]
NEERKKURI:
Niram
Manam
Edai
Nurai
Enjal
NEIKKURI
Date:
Station:
Signature of the Guide Signature of the Investigator
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbarspondylosis) with the
evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga Nirkundi
thailam” (external) and Varmam Therapy.
FORM IV :
 LABORATORY INVESTIGATIONS PROFORMA
1. SERIAL NO OF THE CASE: …………………
2.OP / IP NO: ......................................
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................
A) BLOOD INVESTIGATIONS:
BLOOD INVESTIGATIONS BEFORE
TREATMENT
AFTER
TREATMENT
Hb ( gm/dL)
T.RBC (millions cells / Cu.mm)
ESR (mm) ½ hr.
1 hr.
T.WBC (Cells / Cu.mm)
Differential
Count (%)
Polymorphs
Lymphocytes
Monocytes
Eosinophils
Basophils
BLOOD INVESTIGATIONS BEFORE
TREATMENT
AFTER
TREATMENT
Blood glucose (mg/dl) Random
PP
Serum Calcium
Renal Function Test Blood urea
Serum creatinine
B) URINE INVESTIGATIONS:
URINE
INVESTIGATIONS
BEFORE TREATMENT AFTER TREATMENT
Albumin
 Sugar
Deposits
C) RADIOLOGICAL EXAMINATION
X-Ray  Lumbar Spine AP View, Lateral View
BEFORE TMT AFTER TMT
Sonographic
changes
Date:
Station:
Signature of the Guide:  Signature of the Investigator:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbarspondylosis) with the
evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga Nirkundi
thailam” (external) and Varmam Therapy.
FORM V: INFORMED CONSENT FORM
“I have read the foregoing information, or it has been read to me. I have had the
opportunity to ask questions about it and any questions I have asked have been answered to my
satisfaction.
            I   consent voluntarily to participate in this study and understand that I have the   right
to withdraw from the study at any time without in any way it affecting my further medical
care”.
"I have received a copy of the information sheet/consent form".
Date:
Signature of the participant:
In case of illiterate participant
 “I have witnessed the accurate reading of the consent form to the potential participant,
and the individual has had the opportunity to ask questions. I confirm that the individual has
given consent freely.”
Signature of a witness                                            Left thumb Impression of the Participant
(Selected by the participant bearing no connection with the survey team)
Date:
Station:
Signature of the Guide: Signature of the Investigator:
Signature of participant:
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢, ¦ºý¨É-106
«È¢»÷ «ñ½¡ ÁÕòÐÅÁ¨É, ¦ºý¨É
jz;lfthj §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý நாக
À¡¢¸¡¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ.
´ôÒ¾ø ÀÊÅõ
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð
¿¡ý þó¾ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌ ÒÃ¢Ôõ Å¨¸Â¢ø
±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý.
§¾¾¢: ¨¸¦Â¡ôÀõ:
þ¼õ: ¦ÀÂ÷    :
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø
±ýÉ¢¼õ  þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ ÁÕòÐÅ
ÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ ¸ñ¸¡½¢ì¸×õ, «¾¨É À¡Ð¸¡ì¸×õ
ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢ «Ç¢ìÌõ Å¨¸Â¢ø ¬ö×
ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì ÜÈôÀð¼Ð.
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì ¦¸¡ñÎ
jz;lfthj §¿¡öì¸¡É நாக ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ
ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý.
§¾¾¢ : ¨¸¦Â¡ôÀõ :
þ¼õ :          ¦ÀÂ÷ :
§¾¾¢  : º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ :
þ¼õ  : ¦ÀÂ÷ :
¯È×Ó¨È :
Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ :
¬Ã¡öîº¢Â¡Ç÷ ¨¸¦Â¡ôÀõ:
GOVERNMENT SIDDHA MEDICAL COLLEGE, CHENNAI
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbarspondylosis) with the
evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga Nirkundi
thailam” (external) and Varmam Therapy.
FORM VI - WITHDRAWAL FORM
SI NO:
OP / IP NO:
NAME:
AGE / GENDER :
DATE OF TRIAL COMMENCEMENT:
DATE OF WITHDRAWAL FROM TRIAL:
REASONS FOR WITHDRAWAL:
• Long absence at reporting : Yes/ No
• Irregular treatment: Yes/ No
• Shift of locality : Yes/No
• Increase in severity of symptoms: Yes/No
• Development of severe adverse drug reactions: Yes/No
Date:
Station:
Signature of the Guide: Signature of the Investigator:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparaitive clinical trial on Thandaga vatham (Lumbar spondylosis) with the
evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga Nirkundi
Thailam” (external) and Varmam Therapy.
FORM VII – PATIENT INFORMATION SHEET
Name of Co- Investigator: C R Sreedhana
Name of the college:  Govt. Siddha Medical College
Arumbakkam
 Chennai-106.
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN CLINICAL
TRIAL.
C R Sreedhana studying M.D (Siddha) at Govt.Siddha Medical College, Chennai,  is doing
a clinical trial on ‘‘Thandaga vatham (Lumbar spondylosis). It is becoming a most common
disease, occurring throughout the world. In this regard, I am in need to ask you few questions. I
will maintain confidentiality of your comments and data obtained. There will be no risk of
disclosing your identity and no physical, psychological or professional risk is involved by taking
part in this study. Taking part in this study is voluntary. No compensation will be paid to you for
taking  part in this study.
           You can choose not to take part. You can choose not to answer a specific question. There is
no specific benefit for you if you take part in the study. However, taking part in the study may be
of benefit to the community, as it may help us to understand the problem of defaulters and
potential solutions.
             If you agree to be a participant in this study, you will be included in the study primarily by
signing the consent form and then you will be given the internal medicine “NAGA
CHENDHURAM” twice a day with water for 48 days.
The information I am collecting in this study will remain between you and the Co-
investigator (myself). I will ask you few questions through a questionnaire. I will not write your
name on this form. I will use a code instead.
The questionnaire will take approximately 20 minutes of your time.
If you wish to find out more about this study before taking part, you can ask me all the
questions you want or contact C R Sreedhana, PG Scholar cum Co- investigator of this study,
attached to Govt. Siddha Medical College, Chennai-106. You can also contact the Member-
secretary of Ethics committee, Govt.Siddha Medical College, Chennai.
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢, ¦ºý¨É-106
«È¢»÷ «ñ½¡ ÁÕòÐÅÁ¨É, ¦ºý¨É
jz;lfthj §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý நாக
À¡¢¸¡¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ
¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷: ÁÕòÐÅ÷.
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷ : «ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢
«ÕõÀ¡ì¸õ,
¦ºý¨É-106
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢Â¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý
ÁÕòÐÅ÷. , jz;lfthj ±ýÛõ §¿¡Â¢ø ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø
®ÎÀðÎû§Çý.
þÐ ÀÃÅì ÜÊÂ §¿¡ö «øÄ.
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì §¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ô
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý.
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ நாக
130 mg 2 §Å¨Ç (¸¡¨Ä, Á¡¨Ä) ¯½×ìÌ À¢ý 48 ¿¡ð¸û ¯ð¦¸¡ûÇ
§ÅñÎõ. ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 7 ¿¡ð¸ÙìÌ ´ÕÓ¨È
 ÁÕòÐÅÁ¨ÉìÌ ÅÃ §ÅñÎõ.
þó¾ ÁÕóÐ º¢ÈôÀ¡¸ jz;lfthj §¿¡öì¸¡¸ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø
ÜÈôÀðÎûÇÐ.
þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç «ÛÁ¾¢ò¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø
±ô§À¡Ð §ÅñÎÁ¡É¡Öõ ¬Ã¡öîº¢Â¢ø þÕóÐ Å¢Ç¸¢ì ¦¸¡ûÇ ¯Ã¢¨Á ¯ûÇÐ.
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ ÁüÈ Å¢ÀÃí¸ÙìÌõ
¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷: , (Àð¼ §Áü ÀÊôÀ¡Ç÷ º¢ò¾ ÁÕòÐÅ Ð¨È)
«Å÷¸¨Ç ±ó¾ §¿Ãò¾¢Öõ ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ ¨¸ô§Àº¢ ±ñ: 8190816643
 §ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ ¾ì¸ «ÛÁ¾¢î º¡ýÚ (IEC) ¦ÀÈôÀðÎûÇÐ.
þó¾ ÁÕóÐ ÓüÈ¢Öõ À¡Ð¸¡ôÀ¡É  ¦À¡Õð¸¨Çì ¦¸¡ñÎ ¾Â¡Ã¢ì¸ôÀðÎûÇÐ. Àì¸
Å¢¨Ç×¸¨Ç ²üÀÎò¾¡Ð.
§ÁÖõ ¯½× Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ  ¸¡ìÌÁ¡Ú «È¢×Úò¾
ÀÎ¸¢ÈÐ.
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ ±É
¯Ú¾¢«Ç¢ì¸¢§Èý.
þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ô À¼ Á¡ð¼¡Ð.
þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø «È¢»÷ «ñ½¡
ÁÕòÐÅÁ¨ÉÂ¢ø, ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
An open comparative clinical trial on Thandaga vatham (Lumbar spondylosis)
with the evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga
Nirkundi Thailam” (external) and Varmam Therapy
FORM IV D
DIETARY ADVICE FORM
§º÷ì¸ ÜÊÂ ¯½×¸û:
 ¸¡ö¸û:¸ò¾Ã¢À¢ïÍ,ÓÕí¨¸À¢ïÍ,,«Å¨ÃÀ¢ïÍ,
                           ¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ.
 ¸£¨Ã¸û:¸Ã¢º¡¨Ä,¦À¡ýÉ¡í¸ñ½¢,Á½ò¾ì¸¡Ç¢,
                  ÓÕí¨¸¸£¨Ã,Àº¨Ä¸£¨Ã,º¢Ú¸£¨Ã, ¸È¢§ÅôÀ¢¨Ä ¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ.
 ÀÆí¸û:Á¡Ð¨Ç,¬ôÀ¢û,Å¡¨Æ,§ÀÃ£î¨º,«ò¾¢,
¾¢Ã¡ð¨º,¦¸¡öÂ¡,¬ÃïÍ,±ÖÁ¢î¨º, ¿¡Åø,¾ì¸¡Ç¢,¬¸¢Â¨Å §º÷ì¸
§ÅñÎõ.
 ¾¡É¢Âí¸û:§¸¡Ð¨Á,µðŠ,§º¡Â¡À£ýŠ,Àð¼¡½¢,
¦¸¡ñ¨¼¸¼¨Ä,±û,À¡¾¡õ ¬¸¢Â¨Å
                       §º÷ì¸ §ÅñÎõ.
 «¨ºÅõ:¦ÅûÇ¡ðÎ¸È¢,®Ãø,±ÖõÒÁˆ¨ƒ,
¬¸¢Â¨Å §º÷ì¸ §ÅñÎõ.
§º÷ì¸ Ü¼¡¾¨Å¸û:
 Áó¾ô ¦À¡Õû
 ¯Õ¨Çì ¸¢ÆíÌ.
 «¸ò¾¢ì¸£¨Ã.
 ÒÇ¢ôÒ.
 Ò¨¸Â¢¨Ä
 ÁÐ «ÕóÐ¾ø
ÁÕòÐÅ «È¢×¨Ã:
                           GOVERNMENT SIDDHA MEDICAL COLLEGE
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM
An open comparative clinical trial on Thandaga vatham (Lumbar Spondylosis)
with the evaluation of Siddha trial drugs “Naga Chendhurum” (Internal), “Moolayoga
Nirkundi Thailam” (external) and Varmam Therapy
                                  FORM IX - ADVERSE REACTION FORM
SERIAL NO:
OP  NO:
NAME:
 AGE:
 GENDER:
DATE OF TRIAL COMMENCEMENT:
DATE OF OCCURRENCE OF THE ADVERSE REACTION:
TIME:
DESCRIPTION OF ADVERSEREACTION:
Date:
Station:
Signature of the Guide:                                                      Signature of the Investigator:
